Rak v SlovenijiCancer in Slovenia annual reportletno porocilo orem ipsum 2018 Rak v Sloveniji Cancer in Slovenia 2018 Naslov Title Rak v Sloveniji 2018 / Cancer in Slovenia 2018 Uredniški odbor Editorial Board Vesna Zadnik, glavna urednica / editor-in-chief Gorana Gašljevic, Marko Hocevar, Katja Jarm, Vera Pompe-Kirn, Primož Strojan, Sonja Tomšic, Branko Zakotnik in Tina Žagar Racunalniška obdelava EDP Analysis Nika Bric, Tina Žagar, Katarina Lokar, Miran Mlakar in Mojca Birk Oblikovanje in priprava za tisk Design and Typesetting Nika Bric Tisk Printing Tisk Žnidaric d.o.o. Izdajatelj Published by Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, SloveniaEpidemiologija in register raka / Epidemiology and Cancer RegistryRegister raka Republike Slovenije / Slovenian Cancer Registry Naklada Published in 500 izvodov / 500 copies Nasvet za citiranje Recommended Reference Rak v Sloveniji 2018. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2021. Cancer in Slovenia 2018. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2021. Osebje Registra raka Republike Slovenije Staff of the Slovenian Cancer Registry Vesna Zadnik, vodja / head Agata Campa, Vesna Drolec, Maruška Ferjancic, Katja Hribar, Andrej Kirn, Katja Kolenc Mokotar, Andrej Krašovec, Martina Omerzo, Branka Pestotnik, Sabina Prvinšek, Polona Rus, Darja Strle, Laura Šeneker Zupanc, Franciška Škrlec, Polona Škulj, Urška Tomšic, Boštjan Zavratnik, Brigita Zore, Mojca Birk, Nika Bric, Ana Mihor, Miran Mlakar, Katarina Lokar, Sonja Tomšic, Tina Žagar Naslov Correspondence to Register raka Republike Slovenije / Slovenian Cancer Registry Onkološki inštitut Ljubljana / Institute of Oncology LjubljanaZaloška c. 2, 1001 Ljubljana, p.p. 2217, SlovenijaTelefon / Phone: + 386 1 5879 450 E-pošta / E-mail: register@onko-i.si Spletna stran / Web site: http://www.onko-i.si/rrs/ http://www.slora.si/ http://www.onko-i.si/eng/crs/ http://www.slora.si/en/ Kazalo Contents3Kazalo Uvodnik 6 Editorial 7 Podatki 8 Viri podatkov 8 Obdelava podatkov 9 Kakovost podatkov 10 Data 12 Data Sources 12 Data Processing 13 Data Quality 14 Rak v Sloveniji 15 Osnovni podatki o raku v Sloveniji 2018 16 Starost bolnikov 16 Casovni trend 16 Najpogostejši raki 18 Trend najpogostejših rakov 21 Redki raki 22 Preživetje 23 Primerjava z Evropo 26 Cancer in Slovenia 28 Basic figures on cancer in Slovenia 2018 28 Age of patients 28 Time trends 29 Most frequent cancers 29 Time trends for most frequent cancers 29 Rare cancers 30 Survival 30 Comparisons with Europe 31 Incidenca Incidence 32 Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2009-2018 in 2021. 32 Table 1: Observed and estimated cancer incidence by sex, Slovenia 2009-2018 and 2021. 32 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2018. 33 Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2018. 33 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2018. 34 Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2018. 34 Contents 3Kazalo Uvodnik 6 Editorial 7 Podatki 8 Viri podatkov 8 Obdelava podatkov 9 Kakovost podatkov 10 Data 12 Data Sources 12 Data Processing 13 Data Quality 14 Rak v Sloveniji 15 Osnovni podatki o raku v Sloveniji 2018 16 Starost bolnikov 16 Casovni trend 16 Najpogostejši raki 18 Trend najpogostejših rakov 21 Redki raki 22 Preživetje 23 Primerjava z Evropo 26 Cancer in Slovenia 28 Basic figures on cancer in Slovenia 2018 28 Age of patients 28 Time trends 29 Most frequent cancers 29 Time trends for most frequent cancers 29 Rare cancers 30 Survival 30 Comparisons with Europe 31 Incidenca Incidence 32 Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2009-2018 in 2021. 32 Table 1: Observed and estimated cancer incidence by sex, Slovenia 2009-2018 and 2021. 32 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2018. 33 Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2018. 33 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2018. 34 Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2018. 34 Contents Tabela 4a: Table 4a: Tabela 4b: Table 4b: Tabela 4c: Table 4c: Tabela 5: Table 5: Incidenca mikroskopsko (histološko in citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2018. 38 Incidence of microscopicaly (histologically and cytologically) confirmed cancer cases by morphological type, Slovenia 2018. 38 Incidenca malignih neoplazem limfaticnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2018. 42 Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2018. 42 Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2018. 43 Incidence of non-Hodgkin’s lymphomas (NHL) by cancer site, Slovenia 2018. 43 Incidenca raka po stadiju, Slovenija 2018. Cancer incidence by stage, Slovenia 2018. Prevalenca Prevalence 44 44 46 Tabela 6: Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2018. 46 Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2018. 46 Umrljivost Mortality 47 Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2018. Vir: Nacionalni inštitut za javno zdravje 47 Table 7: Cancer mortality by age and by sex, Slovenia 2018. Source: National Institute of Public Health 47 Preživetje Survival 48 Tabela 8: Eno- in pet-letno cisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2014–2018. 48 Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2014–2018 by sex. 48 Zdravljenje Treatment 49 Tabela 9a: Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2018, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL). 49 Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2018, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given). 49 Tabela 9b: Število bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2018, ki so bili v okviru prvega zdravljenja operirani, po ustanovi posega. 50 Table 9b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2018, that were treated by surgery during their first treatment by treatment institution. 50 Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2018, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po ustanovi zdravljenja. 51 Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2018, that were treated by systemic therapy during their first treatment by treatment institution. 51 Breme najpogostejših rakov Cancer Fact Sheets 52 Vsi raki / All cancer sites (C00–C96) 52 Prostata / Prostate (C61) 53 Pljuca in sapnik / Lung and trachea (C33, C34) 54 Dojka / Breast (C50) 55 Debelo crevo in danka / Colon and rectum (C18–C20) 56 Koža, razen melanoma / Skin, non-melanoma (C44) 57 Kožni melanom / Malignant melanoma of skin (C43) 58 Glava in vrat / Head and neck (C00–C14, C30–C32) 59 Maternicno telo / Corpus uteri (C54) 60 Ne-Hodgkinov limfom / Non-Hodgkin’s lymphoma (C82–C85) 61 Pojmovnik 62 Glossary 63 Uvodnik 6UvodnikRegister raka Republike Slovenije (RRRS) je v svetovnem merilu prepoznan kot eden najstarejših in najkvalitetnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od zacetka deluje v okviru Onkološkega inštituta Ljubljana. Zacetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje, profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporocili Svetovne zdravstvene organizacije zavedala, da je uspešnost in ucinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoce objektivno ovre- dnotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v casu. Leta 2020 smo praznovali 70. letnico neprekinjenega delovanja slovenskega Registra raka. Castitljivo obletnico smo obeležili tudi s pripravo zgodovinskega pregleda delovanja Registra v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazane na naši spletni strani (www. onko-i.si/rrs) ter v posebej za to priložnost izdani brošuri. Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so sku- paj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za oce- njevanje bremena rakavih bolezni v državi. Pomembni so za nacrtovanje in ocenjevanje Državnega programa obvladovanja raka na podrocju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za nacrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolez- ni (osebje, medicinska oprema, bolnišnicne zmogljivosti). Dragoceni so za klinicne in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje ucinkovitosti presejalnih programov. Z natancnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v okviru klinicnih registrov pa lahko, poleg zgoraj opisanega spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišnicnega registra Onkološkega inštituta Ljubljana, ki že ves cas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogocajo podrobnejši pregled nad bolniki, zdravljenimi na inštitutu. Redna letna porocila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokov- ne javnosti in drugih zainteresiranih. Ker je potreben cas za izdajo letnega porocila nekoliko daljši, v porocilih zadnja leta objavljamo tudi pricakovano incidenco raka v letu, ko je porocilo izdano (v tok- ratnem porocilu za leto 2021). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga po zacetnih crkah besed »Slovenija in rak« poimenovali SLORA. Dostopen je na elektronskem naslovu www.slora.si. Omogoca preprost in hiter dostop do vecine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoca primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in po svetu. Vsem, ki ste kakorkoli prispevali k izdaji tega porocila, tako sodelavcem Registra raka kot tudi vsem zdravnikom in klinicnemu osebju po vsej državi, ki ste nam posredovali porocila o diagnozi in zdra- vljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem. prof. dr. Vesna Zadnik, dr. med. vodja Registra raka Republike Slovenije Ljubljana, september 2021 6UvodnikRegister raka Republike Slovenije (RRRS) je v svetovnem merilu prepoznan kot eden najstarejših in najkvalitetnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od zacetka deluje v okviru Onkološkega inštituta Ljubljana. Zacetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje, profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporocili Svetovne zdravstvene organizacije zavedala, da je uspešnost in ucinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoce objektivno ovre- dnotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v casu. Leta 2020 smo praznovali 70. letnico neprekinjenega delovanja slovenskega Registra raka. Castitljivo obletnico smo obeležili tudi s pripravo zgodovinskega pregleda delovanja Registra v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazane na naši spletni strani (www. onko-i.si/rrs) ter v posebej za to priložnost izdani brošuri. Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so sku- paj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za oce- njevanje bremena rakavih bolezni v državi. Pomembni so za nacrtovanje in ocenjevanje Državnega programa obvladovanja raka na podrocju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za nacrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolez- ni (osebje, medicinska oprema, bolnišnicne zmogljivosti). Dragoceni so za klinicne in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje ucinkovitosti presejalnih programov. Z natancnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v okviru klinicnih registrov pa lahko, poleg zgoraj opisanega spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišnicnega registra Onkološkega inštituta Ljubljana, ki že ves cas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogocajo podrobnejši pregled nad bolniki, zdravljenimi na inštitutu. Redna letna porocila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokov- ne javnosti in drugih zainteresiranih. Ker je potreben cas za izdajo letnega porocila nekoliko daljši, v porocilih zadnja leta objavljamo tudi pricakovano incidenco raka v letu, ko je porocilo izdano (v tok- ratnem porocilu za leto 2021). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga po zacetnih crkah besed »Slovenija in rak« poimenovali SLORA. Dostopen je na elektronskem naslovu www.slora.si. Omogoca preprost in hiter dostop do vecine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoca primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in po svetu. Vsem, ki ste kakorkoli prispevali k izdaji tega porocila, tako sodelavcem Registra raka kot tudi vsem zdravnikom in klinicnemu osebju po vsej državi, ki ste nam posredovali porocila o diagnozi in zdra- vljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem. prof. dr. Vesna Zadnik, dr. med. vodja Registra raka Republike Slovenije Ljubljana, september 2021 Editorial7 Editorial The Slovenian Cancer Registry (SCR) is recognized as one of the oldest and best quality population- based cancer registries in Europe and the world. Founded in 1950, from the very beginning it has ope- rated under the auspices of the Institute of Oncology Ljubljana. It was established thanks to the hard work and visionary ideas of its founder and first director, prof dr Božena Ravnihar. Many years before the World Health Organization endorsed such measures, she recognized that the effectiveness and efficiency of the efforts of health services and health policy to manage cancer can be objectively evaluated only with appropriate data on the burden of disease and monitoring of changes over time. In 2020, the Slovenian Cancer Registry celebrated the 70th anniversary of continuous operation. To mark this venerable anniversary, we have also prepared a historical overview of the work of the Registry in all these years. Readers interested in learning more can find historical facts and anecdotes on our website (www.onko-i.si/eng/rrs) and in a brochure published specially for this occasion. Data on new cancer cases (incidence), survival and prevalence amassed in the Cancer Registry, to- gether with mortality data collected and processed by the National Institute of Public Health, form the basis for assessing cancer burden in the country. The Registry’s data are important for planning and evaluation of the National Cancer Control Programme for the primary and secondary prevention of cancer, diagnostics, treatment and rehabilitation, as well as for planning for the facilities and re- sources needed for cancer management (staff, medical equipment, hospital facilities). They are also extremely useful for Slovenian and international clinical and epidemiological research and for evalua- ting the effectiveness of screening programmes. In addition, precise data on diagnosis and treatment that the Cancer Registry manages in clinical registries can be used to monitor the quality of treatment received by oncology patients. The Hospital Registry of the Institute of Oncology Ljubljana, which has always been managed as part of the nationwide Cancer Registry and is in large part also supplied with Registry's data, provides a more detailed overview of patients treated at the Institute. Regular annual reports of the Slovenian Cancer Registry aim to directly inform the professional com- munity and other stakeholders. Given that it takes a fair amount of time to prepare and publish the annual report, the projected cancer incidence for the year when the report is issued (i.e. for 2021 in this report) has in recent years been included in the report. Since 2010, our SLORA interactive web portal – www.slora.si – has also been up and running; its name is based on the initial letters of the words Slovenija in rak (Slovenia and cancer). It provides easy and quick access to most cancer data in Slovenia and, with useful links to foreign databases, enables the comparison of cancer burden in Slovenia with other countries in Europe and in the world. On behalf of the Editorial Board, I would like to sincerely thank everyone who has contributed to the publication of this report, including the staff of the Cancer Registry along with all the physicians and clinical staff across the country who have provided us with reports on cancer diagnosis and treatment. prof. Vesna Zadnik, MD, PhD director of the Slovenian Cancer Registry Ljubljana, September 2021 7 Editorial The Slovenian Cancer Registry (SCR) is recognized as one of the oldest and best quality population- based cancer registries in Europe and the world. Founded in 1950, from the very beginning it has ope- rated under the auspices of the Institute of Oncology Ljubljana. It was established thanks to the hard work and visionary ideas of its founder and first director, prof dr Božena Ravnihar. Many years before the World Health Organization endorsed such measures, she recognized that the effectiveness and efficiency of the efforts of health services and health policy to manage cancer can be objectively evaluated only with appropriate data on the burden of disease and monitoring of changes over time. In 2020, the Slovenian Cancer Registry celebrated the 70th anniversary of continuous operation. To mark this venerable anniversary, we have also prepared a historical overview of the work of the Registry in all these years. Readers interested in learning more can find historical facts and anecdotes on our website (www.onko-i.si/eng/rrs) and in a brochure published specially for this occasion. Data on new cancer cases (incidence), survival and prevalence amassed in the Cancer Registry, to- gether with mortality data collected and processed by the National Institute of Public Health, form the basis for assessing cancer burden in the country. The Registry’s data are important for planning and evaluation of the National Cancer Control Programme for the primary and secondary prevention of cancer, diagnostics, treatment and rehabilitation, as well as for planning for the facilities and re- sources needed for cancer management (staff, medical equipment, hospital facilities). They are also extremely useful for Slovenian and international clinical and epidemiological research and for evalua- ting the effectiveness of screening programmes. In addition, precise data on diagnosis and treatment that the Cancer Registry manages in clinical registries can be used to monitor the quality of treatment received by oncology patients. The Hospital Registry of the Institute of Oncology Ljubljana, which has always been managed as part of the nationwide Cancer Registry and is in large part also supplied with Registry's data, provides a more detailed overview of patients treated at the Institute. Regular annual reports of the Slovenian Cancer Registry aim to directly inform the professional com- munity and other stakeholders. Given that it takes a fair amount of time to prepare and publish the annual report, the projected cancer incidence for the year when the report is issued (i.e. for 2021 in this report) has in recent years been included in the report. Since 2010, our SLORA interactive web portal – www.slora.si – has also been up and running; its name is based on the initial letters of the words Slovenija in rak (Slovenia and cancer). It provides easy and quick access to most cancer data in Slovenia and, with useful links to foreign databases, enables the comparison of cancer burden in Slovenia with other countries in Europe and in the world. On behalf of the Editorial Board, I would like to sincerely thank everyone who has contributed to the publication of this report, including the staff of the Cancer Registry along with all the physicians and clinical staff across the country who have provided us with reports on cancer diagnosis and treatment. prof. Vesna Zadnik, MD, PhD director of the Slovenian Cancer Registry Ljubljana, September 2021 Podatki8PodatkiViri podatkov Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vkljucevanjem razlicnih vi- rov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju razlicnih zbirk se uporablja enotni državni identifikator EMŠO. Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdravi- jo in spremljajo. Tradicionalno bolnišnice porocajo Registru raka na posebnem formularju Prijavnica rakave bolezni. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Univerzitetni Kliniki Golnik zbi- rajo podatke za Prijavnico v lastnem bolnišnicnem registru ter jih od tam v Register raka posredujejo elektronsko; v ostalih bolnišnicah Prijavnice izpolnjujejo zdravniki, ki bolnika obravnavajo, ali pooblaš- ceno osebje. Skladno s cilji Državnega programa obvladovanja raka 2017–2021 smo v letu 2019 zaceli uvajati tako imenovano aktivno registracijo, kjer bolnišnice v svojih informacijskih sistemih pripravijo in Registru raka posredujejo seznam bolnikov, ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno porocanje s Prijavnicami je tako uki- njeno. Za zbolele v letu 2018, ki so prikazani v tem porocilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem klinicnem centru Maribor, Pediatricni kliniki ter Klinicnem oddelku za hematologijo Univerzitetnega klinicnega centra Ljubljana. Dopolnilni vir podatkov Registra raka so zdravniška porocila o vzroku smrti, ki nam jih pošilja Nacio- nalni inštitut za javno zdravje RS, ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na mater- nicnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem crevesu in danki. Za izracun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobi- mo dnevno preko varnih spletnih povezav iz Centralnega registra prebivalstva (CRP). Podrobne ana- Državne zdravstvene podatkovne zbirke: - Register umrlihUpravniregistri: - CRP- GURS Presejalni programi: - ZORA- Svit- DORA Zdravstveni zavodi: - Pasivna ali aktivna prijava Bolnišnicni register: - OIL- Golnik Klinicne in populacijske raziskave REGISTERRAKA RS 8PodatkiViri podatkov Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vkljucevanjem razlicnih vi- rov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju razlicnih zbirk se uporablja enotni državni identifikator EMŠO. Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdravi- jo in spremljajo. Tradicionalno bolnišnice porocajo Registru raka na posebnem formularju Prijavnica rakave bolezni. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Univerzitetni Kliniki Golnik zbi- rajo podatke za Prijavnico v lastnem bolnišnicnem registru ter jih od tam v Register raka posredujejo elektronsko; v ostalih bolnišnicah Prijavnice izpolnjujejo zdravniki, ki bolnika obravnavajo, ali pooblaš- ceno osebje. Skladno s cilji Državnega programa obvladovanja raka 2017–2021 smo v letu 2019 zaceli uvajati tako imenovano aktivno registracijo, kjer bolnišnice v svojih informacijskih sistemih pripravijo in Registru raka posredujejo seznam bolnikov, ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno porocanje s Prijavnicami je tako uki- njeno. Za zbolele v letu 2018, ki so prikazani v tem porocilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem klinicnem centru Maribor, Pediatricni kliniki ter Klinicnem oddelku za hematologijo Univerzitetnega klinicnega centra Ljubljana. Dopolnilni vir podatkov Registra raka so zdravniška porocila o vzroku smrti, ki nam jih pošilja Nacio- nalni inštitut za javno zdravje RS, ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na mater- nicnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem crevesu in danki. Za izracun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobi- mo dnevno preko varnih spletnih povezav iz Centralnega registra prebivalstva (CRP). Podrobne ana- Državne zdravstvene podatkovne zbirke: - Register umrlihUpravniregistri: - CRP- GURS Presejalni programi: - ZORA- Svit- DORA Zdravstveni zavodi: - Pasivna ali aktivna prijava Bolnišnicni register: - OIL- Golnik Klinicne in populacijske raziskave REGISTERRAKA RS Podatki9lize prostorske razporeditve raka nam omogocata tocno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS (GURS). Pri razporeditvi pre- bivalcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni in ne tudi o zacasnem naslovu, kot je upoštevano v pripravi števila prebivalcev po klasicni »statisticni« definiciji. Pri izracunavanju in interpretiranju vecine kazalni- kov bremena raka so poleg podatkov o bolnikih kljucni tudi nacionalni podatki o številu prebivalcev in njihovi starostni strukturi. Za Slovenijo je tocno število in starostna struktura prebivalcev na voljo za popisna leta že ves cas registracije raka. Nacio- nalni popis prebivalstva je bil pripravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izracunu kazalnikov predpostavili, da je bila med dvema popisnima le- toma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoce dobiti ažuren podatek o številu in staro- stni strukturi prebivalcev. V letnih porocilih uporab- ljamo podatek o prebivalcih na datum 1. julija po- sameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statisticnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupi- nah za celotno Slovenijo za leto 2018 so prikazani v tabeli. Obdelava podatkov Podatke, prispele v Register raka, posebej usposobljene medicinske sestre v procesu registracije ko- dirajo v skladu z mednarodnimi, nacionalnimi in internimi pravili. Lokacija tumorja Za razvršcanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statisticne namene (MKB-10), pred tem pa smo uporabljali osmo. Od leta 1993 je obvezno prijavljanje sprememb maternicnega vratu, oznacenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, oznacene s šifro 234.0 (karcinom in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelij- ske spremembe maternicnega vratu uvršcene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03). Starostna skupina Age group Skupaj All Moški Males Ženske Females 0-4 103.023 52.936 50.087 5-9 111.021 57.228 53.793 10-14 97.787 50.109 47.678 15-19 92.599 47.982 44.617 20-24 100.852 52.467 48.385 25-29 115.511 60.298 55.213 30-34 137.408 72.138 65.270 35-39 154.470 81.402 73.068 40-44 154.636 81.130 73.506 45-49 145.749 75.583 70.166 50-54 154.333 78.260 76.073 55-59 149.384 75.354 74.030 60-64 145.944 72.635 73.309 65-69 128.962 62.728 66.234 70-74 89.608 40.840 48.768 75-79 79.372 33.536 45.836 80-84 58.051 21.611 36.440 85+ 51.340 13.997 37.343 Skupaj / Total 2.070.050 1.030.234 1.039.816 Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2018. Population of Slovenia by age and sex on July 1st 2018. 9lize prostorske razporeditve raka nam omogocata tocno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS (GURS). Pri razporeditvi pre- bivalcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni in ne tudi o zacasnem naslovu, kot je upoštevano v pripravi števila prebivalcev po klasicni »statisticni« definiciji. Pri izracunavanju in interpretiranju vecine kazalni- kov bremena raka so poleg podatkov o bolnikih kljucni tudi nacionalni podatki o številu prebivalcev in njihovi starostni strukturi. Za Slovenijo je tocno število in starostna struktura prebivalcev na voljo za popisna leta že ves cas registracije raka. Nacio- nalni popis prebivalstva je bil pripravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izracunu kazalnikov predpostavili, da je bila med dvema popisnima le- toma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoce dobiti ažuren podatek o številu in staro- stni strukturi prebivalcev. V letnih porocilih uporab- ljamo podatek o prebivalcih na datum 1. julija po- sameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statisticnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupi- nah za celotno Slovenijo za leto 2018 so prikazani v tabeli. Obdelava podatkov Podatke, prispele v Register raka, posebej usposobljene medicinske sestre v procesu registracije ko- dirajo v skladu z mednarodnimi, nacionalnimi in internimi pravili. Lokacija tumorja Za razvršcanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statisticne namene (MKB-10), pred tem pa smo uporabljali osmo. Od leta 1993 je obvezno prijavljanje sprememb maternicnega vratu, oznacenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, oznacene s šifro 234.0 (karcinom in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelij- ske spremembe maternicnega vratu uvršcene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03). Starostna skupina Age group Skupaj All Moški Males Ženske Females 0-4 103.023 52.936 50.087 5-9 111.021 57.228 53.793 10-14 97.787 50.109 47.678 15-19 92.599 47.982 44.617 20-24 100.852 52.467 48.385 25-29 115.511 60.298 55.213 30-34 137.408 72.138 65.270 35-39 154.470 81.402 73.068 40-44 154.636 81.130 73.506 45-49 145.749 75.583 70.166 50-54 154.333 78.260 76.073 55-59 149.384 75.354 74.030 60-64 145.944 72.635 73.309 65-69 128.962 62.728 66.234 70-74 89.608 40.840 48.768 75-79 79.372 33.536 45.836 80-84 58.051 21.611 36.440 85+ 51.340 13.997 37.343 Skupaj / Total 2.070.050 1.030.234 1.039.816 Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2018. Population of Slovenia by age and sex on July 1st 2018. Morfologija tumorja Pri uvršcanju med maligne bolezni uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvršcamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajcnikov ne uvršcamo vec v kategorijo C56, pac pa v D39.1. Po tretji reviziji so med maligne uvršcene kronicne mieloproliferativne bolezni in mielodisplasticni sindromi (sedaj s topografsko šifro C96.7) in policitemije, ki jih od 2001 uvršcamo v skupino C94. Z razvojem molekularne in genske tehnologije je mogoce natancneje opredeliti vrsto celicnih sprememb, ki nastanejo pri neoplazmah krvotvornega in limfaticnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se veca tudi število razlicnih vrst bolezni, njihovo razvršcanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfaticnega tkiva glede na imunofenotip, genetske spremembe in klinicno sliko. Leta 2008 je bila ta klasifikacija posodobljena in pri klinicnem delu zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfaticnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). Stadij bolezni Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih porocilih pri solidnih tumorjih uporabljamo poenostavljeno razvršcanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, ce bolnik predtem ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvršcen primer bolezni, pri katerem je tumor oznacen s T1 ali T2. Pri dojki, kožnem melanomu in šcitnici so v omejen stadij vkljuceni tudi tumorji T3; pri maternicnem vratu, maternicnem telesu in sarkomih ter pri jajcniku, jajcevodu in trofoblastnih tumorjih v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete podrocne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi podrocne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvršcamo primere, pri katerih je zapisano, da so bili zasevki že prisotni v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, ce je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Dodatno ginekološke tumorje opredeljujemo po klasifikaciji FIGO, pri kožnem melanomu beležimo velikost po Clarku in Breslowu, maligni limfomi pa so opredeljeni po klasifikaciji Ann-Arbor. Kakovost podatkov V Registru raka spremljamo kakovost podatkov z dvema tradicionalnima mednarodno primerljivima posrednima kazalnikoma: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških porocil o vzroku smrti. Vrednosti teh kazalnikov so prikazane v tabeli. Incidenca raka glede na nacin postavitve diagnoze po izbrani primarni lokaciji, Slovenija 2018. Cancer incidence according to basis of diagnosis, Slovenia 2018. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Mikroskopsko potrjeni primeri Microscopically confirmed cases Ugotovljeni z drugimi preiskavami Confirmed by other investigations Registrirani samo iz zdravniških porocil o vzroku smrti Registered from death certificates only Število Number % Število Number % Število Number % C00-C96 Vse lokacije All sites Moški in ženske / Males and females Moški / Males Ženske / Females 15905 8515 7390 15112 8071 7041 95,0 94,8 95,3 752 431 321 4,7 5,1 4,3 41 13 28 0,3 0,2 0,4 C00-C14 Usta in žrelo / Mouth and pharynx 339 335 98,8 3 0,9 1 0,3 C15 Požiralnik / Oesophagus 103 91 88,3 11 10,7 1 1,0 C16 Želodec / Stomach 438 427 97,5 9 2,1 2 0,5 C18 Debelo crevo / Colon 850 810 95,3 32 3,8 8 0,9 C19-C20 Rektum in rektosigmoidna zveza / Rectum and rectosigmoid junction 499 480 96,2 17 3,4 2 0,4 C22 Jetra in intrahepaticni vodi / Liver and intrahepatic bile ducts 231 126 54,5 103 44,6 2 0,9 C23-C24 Žolcnik in žolcevodi / Gallbladder and billiary tract 190 116 61,1 73 38,4 1 0,5 C25 Trebušna slinavka / Pancreas 428 287 67,1 140 32,7 1 0,2 C32 Grlo / Larynx 119 119 100,0 0 0,0 0 0,0 C33-C34 Sapnik, sapnici in pljuca / Trachea, bronchus and lung 1565 1430 91,4 130 8,3 5 0,3 C43 Maligni melanom kože / Malignant melanoma of skin 604 604 100,0 0 0,0 0 0,0 C44 Druge maligne neoplazme kože / Skin, excl. melanoma 3603 3588 99,6 15 0,4 0 0,0 C48-C49 Vezivno in mehko tkivo / Connective and soft tissue 74 73 98,6 1 1,4 0 0,0 C50 Dojka / Breast 1526 1509 98,9 11 0,7 6 0,4 C53 Maternicni vrat / Cervix uteri 108 107 99,1 1 0,9 0 0,0 C54 Maternicno telo / Corpus uteri 351 349 99,4 2 0,6 0 0,0 C56 Jajcnik / Ovary 142 136 95,8 5 3,5 1 0,7 C61 Prostata / Prostate 1680 1636 97,4 42 2,5 2 0,1 C62 Modo / Testis 86 86 100,0 0 0,0 0 0,0 C64-C65 Ledvica z ledvicnim mehom / Kidney with renal pelvis 443 404 91,2 38 8,6 1 0,2 C67 Secni mehur / Bladder 342 330 96,5 12 3,5 0 0,0 C70-C72 Centralni in avtonomni živcni sistem / Central and autonomic nervous system 168 152 90,5 16 9,5 0 0,0 C73 Šcitnica / Thyroid gland 194 194 100,0 0 0,0 0 0,0 C81 Hodgkinov limfom / Hodgkin’s lymphoma 51 51 100,0 0 0,0 0 0,0 C82-C85 Ne-Hodgkinovi limfomi / Non-Hodgkin’s lymphoma 424 424 100,0 0 0,0 0 0,0 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms 142 142 100,0 0 0,0 0 0,0 C91-C95 Levkemije / Leukaemias 351 351 100,0 0 0,0 0 0,0 Data12Data Data Sources Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Can- cer Registry and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data com- pleteness. The unique national identification number (EMŠO) is used to facilitate linkage between different databases. The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registries collect data for the Notification form and then send it electronically to the Cancer Registry; in other hospitals Notification forms are filled in by the attending physicians or by the authorized staff. In accordance with the goals of the Natio- nal Cancer Control Program 2017–2021, in 2019 we began introducing data collection via so-called active registration, where hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting using Notification Forms will gradually be phased out. For patients diagnosed in 2018, whose data are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana, the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Hae- matology at the University Medical Centre Ljubljana. Complementary sources of information for the Cancer Registry are death certificates that we obtain from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed can- cers recorded in three national screening programs: ZORA for detection of precancerous and early National Health Databases: - DeathRegistry Administrative registries: - CPR - SMARS Screening programmes: - ZORA- Svit - DORA Health Institutions: - Passsive or active registration Hospital- based registries: - IOL - Golnik Clinical and demographicresearch SLOVENIAN CANCERREGISTRY 12Data Data Sources Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Can- cer Registry and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data com- pleteness. The unique national identification number (EMŠO) is used to facilitate linkage between different databases. The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registries collect data for the Notification form and then send it electronically to the Cancer Registry; in other hospitals Notification forms are filled in by the attending physicians or by the authorized staff. In accordance with the goals of the Natio- nal Cancer Control Program 2017–2021, in 2019 we began introducing data collection via so-called active registration, where hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting using Notification Forms will gradually be phased out. For patients diagnosed in 2018, whose data are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana, the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Hae- matology at the University Medical Centre Ljubljana. Complementary sources of information for the Cancer Registry are death certificates that we obtain from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed can- cers recorded in three national screening programs: ZORA for detection of precancerous and early National Health Databases: - DeathRegistry Administrative registries: - CPR - SMARS Screening programmes: - ZORA- Svit - DORA Health Institutions: - Passsive or active registration Hospital- based registries: - IOL - Golnik Clinical and demographicresearch SLOVENIAN CANCERREGISTRY cancerous cervical lesions, DORA for early detection of breast cancer, and Svit for detection of precancerous lesions and cancer of the colon and rectum. Calculation of cancer prevalence and survival requires information on the patient’s vital status (whether the person is alive, dead or lost to follow- up). This data is updated daily through secure electronic linkage with the Central Population Registry (CPR). Detailed analyses of the spatial distribution of cancer are only possible if we have accuratelydefined addresses of cancer patients, which we obtain through regular linkage to the Register of Spatial Units of the Surveying and Mapping Authority of the Republic of Slovenia (SMARS). When allocating the population to geographical units, we take into account only the permanent residence of persons at the time of diagnosis and not the temporary one, contrary to the standard “statistical” definition of the population used for calculating the number of inhabitants. In addition to patient data, national population data, especially population size and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration in Slovenia. The census has been performed nearly every 10 years, however until 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, population data are available for any date at the Central Population Registry. In Annual Reports the population data on July 1 of the relevant year are used, obtained from the SiStat Database of the Statistical Office of the Republic of Slovenia. In the table on page 9, the population size of Slovenia in 2018 is presented, stratified by age and sex. Data Processing At the Cancer Registry, specially trained nurses code the data retrieved from Notifications of cancer in accordance with international, national and internal guidelines for cancer registration. Tumour Location Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); previously, the 8th revision was used (ICD-8). In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Until then, only carcinoma in situ (code 234.0) was registered. Thus, comparisons with data for the period 1961–1992 are not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (code D05) and since 1995, all reported intraepithelial carcinomas of the bladder (code D09.0) and all malignant melanomas of Clark level I (code D03) have been registered as well. Tumour Morphology When classifying tumours as malignant, the behaviour digit of the morphology code of the International Classification of Diseases for Oncology is used. Since 2012, the 3rd edition has been in use, including the 2011 updates. In this edition some changes were introduced in terms of morphology and behaviour coding and some new morphology codes were added for tumours that were not coded separately before 2001. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the 3rd edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant neoplasms, the former two being assigned to C96.7, while the polycythaemia is classified under the topography code C94 from the year 2001 on. 13 Development of molecular and genetic technologies has enabled more detailed classification of the type of cellular changes, found in malignant neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. This corresponds to a larger number of disease types with the classification system constantly updating. In 2001, the World Health Organization published a special classification of neoplasms of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and it replaced several other classifications of neoplasms of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology (third revision, 2011 update) follows this classification. Cancer Staging For stage description, a simplified definition of stages at diagnosis is used for solid tumours, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumour has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumour is also included in the localized stage. In cases of uterine cervix, corpus and sarcomas, ovarian cancer, Fallopian tube and trophoblastic tumours only T1 tumour is included in the localized stage. In all these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (with aforementioned exceptions) and/or with regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). A disease with metastases in distant lymph nodes or organs is classified as a distant stage (M1). Stage according to TNM or any other appropriate classification, if available, is also stored in the Cancer Registry database. Additionally, FIGO classification is used for gynaecological tumours, Clark’s level and Breslow’s thickness in skin melanoma, and Ann-Arbor System for lymphomas. Data Quality The quality of information can be directly assessed by the following internationally harmonized standard parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in the table on page 11. Rak v Sloveniji Povzetek Za dodatne podatke o bremenu raka v Sloveniji in svetu obišcite: www.slora.si. . Med rojenimi leta 2018 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk. . Za rakom zboli letno okrog 15.000 Slovencev, skoraj 8.000 moških in vec kot 7.000 žensk, umre pa jih vec kot 6.500, približno 3.500 moških in 3.000 žensk; med nami živi že vec kot 110.000 ljudi, ki so kadarkoli zboleli zaradi ene od rakavih bolezni (prevalenca). . Kljub temu da se ogroženost z rakom zmerno viša, je najvišja pri starejših; med vsemi rakavimi bolniki, zbolelimi leta 2018, je bilo 64 % starejših od 65 let. Ker se slovensko prebivalstvo stara, je samo zaradi vedno vecjega deleža starejših pricakovati, da se bo število novih primerov raka še višalo. . Najpogostejši raki pri nas (kože, prostate, pljuc, dojke ter debelega crevesa in danke) so leta 2018 predstavljali 61 % vseh ugotovljenih rakov. Ti raki so povezani z nezdravim življenjskim slogom, cezmernim soncenjem, nepravilno prehrano, kajenjem in cezmernim pitjem alkoholnih pijac; ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. . Presejalni programi za rake, ki jih priporoca Svet Evropske zveze in smo jih uvedli tudi v Sloveniji, bodo z zgodnjim odkrivanjem zmanjšali umrljivost za rakom dojk, debelega crevesa in danke ter rakom maternicnega vratu; pri slednjih dveh bodo zmanjšali tudi incidenco. . Petletno cisto preživetje odraslih slovenskih bolnikov s katero koli vrsto raka (brez nemelanomskega kožnega), ki so zboleli v obdobju 2014–2018, je bilo 57 %, bolnic pa 61 %. 0 20.000 40.000 60.000 80.000 100.000 120.000 7.390 6.5483.5932.955116.50753.52215.905 Incidenca 8.515 Incidence Umrljivost Mortality Prevalenca Prevalence 62.985 Moški in ženske / Males and females Moški / Males Ženske / Females Slika 1. Breme raka, Slovenija 2018. Figure 1. Cancer burden, Slovenia 2018. Osnovni podatki o raku v Sloveniji 2018 . Leta 2018 je v Sloveniji za rakom zbolelo 15.905 ljudi (8.515 moških in 7.390 žensk). . Starostno standardizirana incidencna stopnja (evropsko prebivalstvo) je bila 502,3/100.000; 584,4 pri moških in 444,5 pri ženskah. Med rojenimi leta 2018 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk. . Leta 2018 je za rakom umrlo 6.548 Slovencev, 3.593 moških in 2.955 žensk. Med nami je živelo 116.507 ljudi (52.522 moških in 62.985 žensk), ki so kadarkoli zboleli za eno od rakavih bolezni (prevalenca). . Med posameznimi slovenskimi regijami ne opažamo bistvenih razlik v bremenu raka. Starost bolnikov . Ceprav se ogroženost z rakom zmerno viša, je najvišja v poznejši starosti; med vsemi rakavimibolniki je leta 2018 kar 66 % moških in 62 % žensk zbolelo po dopolnjeni starosti 65 let. Manj kotpolovico odstotka vseh rakavih bolezni je bilo ugotovljenih pri otrocih in mladostnikih (do 20. leta). . Ker se slovensko prebivalstvo stara, je samo zaradi cedalje vecjega deleža starejših pricakovati, da se bo število novih primerov raka še vecalo. Ocenjujemo, da je bomo leta 2021 zabeležili že 17.170 novih bolnikov. 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ 150.000 100.000 50.000 0 0 500 1000 1500 2000 Število prebivalcev / Population Incidenca / Incidence Slika 2. Število novih primerov vseh rakov (desna stran) po starosti ter primerjava s številom prebivalcev (leva stran) v istih starostnih skupinah, Slovenija 2018. Figure 2. Number of new cancer cases (right side) by age and comparison with the population numbers (left side) in the same age groups, Slovenia 2018. Casovni trend . V splošnem se groba incidencna in umrljivostna stopnja raka vecata. . Groba incidencna stopnja se je v zadnjih dvajsetih letih skoraj podvojila, v zadnjem desetletju seveca za 2,1 % povprecno letno (1,9 % pri moških in 2,5 % pri ženskah). Groba umrljivostna stopnjase je pri moških v zadnjih 10-ih letih vecala povprecno za 1,1 % letno, pri ženskah pa za 1,3 %. . Vec kot polovico tega povecanja lahko pripišemo staranju prebivalstva, saj z daljšo življenjsko dobo lahko tudi vec ljudi docaka to bolezen. Starostno standardizirana kumulativna incidencna stopnja kaže, da se tveganje raka veca pocasneje, pri moških se trend celo obraca navzdol. Spodbudno je tudi, da se umrljivost zaradi raka (ce ne upoštevamo staranja prebivalstva) manjša, predvsem od sredine devetdesetih let naprej, kar kaže na vecjo uspešnost zdravljenja. Leto / Year Incidenca moški Umrljivost moški Incidenca ženske Umrljivost ženske Incidence males Mortality males Incidence females Mortality females Slika 3. Groba letna incidencna in umrljivostna stopnja vseh rakov po spolu spovprecno letno spremembo za zadnjih 10 let, Slovenija 1950-2018. Figure 3. Crude annual incidence and mortality rates for all cancer sites by sex withaverage annual change in last 10 years, Slovenia 1950-2018. Leto / Year Incidenca moški Umrljivost moški Incidenca ženske Umrljivost ženske Incidence males Mortality males Incidence females Mortality females Slika 4. Kumulativna incidencna in umrljivostna stopnja vseh rakov po spolus povprecno letno spremembo v zadnjih 10 letih, Slovenija 1950-2018. Figure 4. Cumulative annual incidence and mortality rates for all cancer sites by sexwith average annual change in last 10 years, Slovenia 1950-2018. 200020052010 20002005201050 40 30 20 10 0 Kumulativna stopnja na 100.000Cumulative rate per 100,000 -0,3 % +1,2* % -2,0* % -0,4* % 1950 800 700 600 500 400 300 200 100 0 Groba stopnja na 100.000Crude rate per 100,000 +1,9* % +2,5* % +1,1* % +1,3* % 1950 1955 1955 1960 1960 1965 1965 1970 1970 1975 1975 1980 1980 1985 1985 1990 1990 1995 1995 2015 2015 2018 2018 Najpogostejši raki . Rak ni ena sama bolezen, temvec vec sto razlicnih. Te lahko vzniknejo v vseh tkivih in organih cloveškega organizma. Razlikujejo se po pogostosti, zdravljenju in izidu, imajo pa tudi razlicne bolj ali manj znane nevarnostne dejavnike. . Pet najpogostejših vrst raka pri nas – kožni (brez melanoma), prostate, pljuc, dojke ter raki debelega crevesa in danke obsegajo 61 % vseh novih primerov rakavih bolezni. . Najpogostejši raki so povezani z nezdravim življenjskim slogom, cezmernim soncenjem, nepravilno prehrano, kajenjem in cezmernim pitjem alkoholnih pijac. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. . Pri moških zavzemata nemelanomski kožni rak in rak prostate vsak petino vseh rakov, sledijo pljucni rak in rak debelega crevesa in danke. Pri ženskah je najpogostejši nemelanomski kožni rak, sledi rak dojke, ki predstavlja petino vseh rakov, nato pa še pljucni rak ter rak debelega crevesa in danke. . Najpogostejši raki se v raznih življenjskih obdobjih pojavljajo razlicno. Pri otrocih in mladostnikih do 20. leta starosti so najpogostejše levkemije, sledijo jim tumorji centralnega in avtonomnega živcnega sistema. Mlajši odrasli moški zbolevajo najvec za rakom mod, pri ženskah v tej starosti pa je na prvem mestu že rak dojke. Moški in ženske Males and females Koža, razen melanoma Skin, excl. melanoma Prostata Prostate Pljuca* Lung* Dojka Breast Debelo crevo in danka* Colorectum* Koža, melanoma Skin, melanoma Glava in vrat* Head and neck* Ledvica z ledvicnim mehom* Kidney with renal pelvis* Želodec Stomach Trebušna slinavka Pancreas Ostalo Other 22,7 10,6 9,8 9,6 8,5 3,8 3,1 2,8 2,7 2,7 23,8 250 5 10 15 20 30 % *Pojasnilo: / Explanation: Glava in vrat / Head and neck (C00-C14, C30-C32) Debelo crevo in danka / Colorectum (C18-C20) Sapnik, sapnici in pljuca / Trachea, bronchus and lung (C33-C34) Ledvica z ledvicnim mehom / Kidney with renal pelvis (C64-C65) Slika 5a. Najpogostejše lokacije raka in njihov odstotni delež pri obeh spolih skupaj, Slovenija 2018. Figure 5a. The leading cancer sites with percentage distribution for both sexes combined, Slovenia 2018. Dojka Breast Koža, razen melanoma Skin, excl. melanoma Ostalo Other Glava in vrat* Head and neck*4,9 Pljuca* Lung* 12,3 10,2 3,8 3,2 21,1 21,8 4,0 12,6 2,0 7,9 20,5 7,3 4,7 2,7 25,3 3,8 20,8 Pljuca* Lung* LevkemijeLeukaemias 2,92,6Trebušna slinavka Pancreas Trebušna slinavka Pancreas 3,32,3Želodec Stomach Želodec Stomach Debelo crevo in danka* Colorectum* Debelo crevo in danka* Colorectum* Maternicno telo Corpus uteri Ledvica z ledvicnim mehom* Kidney with renal pelvis* Mehur Bladder Ne-Hodgkinovi limfomiNon-Hodkgin’s lymphoma Koža, melanom Skin, melanoma Koža, melanom Skin, melanoma Ostalo Other ŽenskeFemalesMoškiMales Prostata Prostate Koža, razen melanoma Skin, non-melanoma 30 %2520 1510 5 0 5 1015202530 % *Pojasnilo / Explanation: Glava in vrat / Head and neck (C00-C14, C30-C32) Debelo crevo in danka / Colorectum (C18-C20) Sapnik, sapnici in pljuca / Trachea, bronchus and lung (C33-C34) Ledvica z ledvicnim mehom / Kidney with renal pelvis (C64-C65) Slika 5b. Najpogostejše lokacije raka in njihov odstotni delež po spolu, Slovenija 2018. Figure 5b. The leading cancer sites with percentage distribution by sex, Slovenia 2018. Starost / Age 0–19 20–49 50–74 75+ Vse starosti / All Ostalo 27,9 Ostalo 24,7 Ostalo 30,7 Ostalo 35,0 Ostalo 33,2 Vezivno in mehko tkivo 8,1 Centralni in avtonomni 18,6 živcni sistem Ženske Females Hodgkinov limfom Šcitnica Šcitnica Koža, melanom Debelo crevo in danka Pljuca 8,1 Levkemije Debelo crevo in danka Maternicni vrat Koža, razen melanoma Kosti Dojka Koža, razen melanoma Dojka Koža, razen melanoma Dojka Koža, razen melanoma Dojka Debelo crevo in danka Debelo crevo in danka Pljuca Pljuca Maternicno telo Maternicno teloMaternicno telo Koža, melanom Koža, melanom Trebušna slinavka 4,7 9,9 22,7 4,3 5,3 7,3 9,1 16,7 32,6 3,4 6,6 7,9 10,3 18,5 22,7 3,8 4,0 5,9 9,9 12,5 28,9 3,8 5,1 7,6 8,1 20,1 22,0 Povprecna letna incidenca 34 838 3548 2523 6943 Starost / Age 0–19 20–49 50–74 75+ Vse starosti / All Ostalo 29,4 Ostalo 35,4 Ostalo 27,9 Ostalo 28,3 Ostalo 31,2 Ne-Hodgkinovi limfomi Kosti Hodgkinov limfom Centralni in avtonomni živcni sistem Ne-Hodgkinovi limfomi8,9 Glava in vrat Debelo crevo in danka Koža, melanom Modo 10,4 Modo 7,9 9,3 11,2 14,5 4,8 6,3 7,9 17,5 Koža, razen melanoma 15,6 Koža, razen melanoma Debelo crevo in danka Pljuca 10,1 18,5 Glava in vrat Koža, melanom 3,7 4,6 11,6 Debelo crevo in danka Pljuca Želodec 10,0 Glava in vrat Ledvica z ledvic. mehom 3,5 Secni mehur5,7 4,2 4,3 9,9 Prostata Debelo crevo in danka 11,0 17,4 Pljuca 13,5 Moški Males Levkemije Koža, razen melanoma 18,7 Prostata Koža, razen melanoma 23,8 Prostata 17,6 24,8 20,2 Average annual incidence 43 555 5016 2556 8169 *Pojasnilo / Explanation: Debelo crevo in danka / Colorectum (C18-C20) Dojka / Breast (C50)Želodec / Stomach (C16) Trebušna slinavka / Pancreas (C25) Maternicni vrat / Cervix uteri (C53) Prostata / Prostate (C61) Pljuca / Lung (C33-C34) Maternicno telo / Corpus uteri (C54)Modo / Testis (C62) Kosti / Bone (C40-C41)Centralni in avtonomni živcni sistem / Central and Ledvica z ledvicnim mehom / Kidney withKoža, melanom / Skin, melanoma (C43) autonomic nervous system (C70-C72) renal pelvis (C64-C65) Koža, razen melanoma / Skin, excl. melanoma (C44) Šcitnica / Thyroid gland (C73) Secni mehur / Bladder (C67) Vezivno in mehko tkivo / Connective and soft tissue (C48-C49) Hodgkinov limfom / Hodgkin’s disease (C81) Ne-Hodgkinovi limfomi (NHL) / Non-Hodgkin’s Glava in vrat / Head and neck (C00-C14, C30-C32) Levkemije / Leukaemias (C91-C95) lymphoma (NHL) (C82-C85) Slika 6. Odstotni deleži najpogostejših rakov po starostnih skupinah in spolu, Slovenija 2014-2018. Figure 6: Percentage distribution of leading cancer sites by age group and sex, Slovenia 2014-2018. Trend najpogostejših rakov .Med pogostejšimi rakavimi boleznimi pri moških se je incidencna stopnja pljucnega raka vecala vse do zacetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 90/100.000. .Pljucnega raka strmo prehitevata rak prostate (povecanje incidencne stopnje za povprecno 1,4 % na leto) in nemelanomski kožni rak (povecanje za povprecno 5,6 % na leto). Izjemno povecan- je incidence raka prostate v prejšnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pac pa predvsem vse širše rabe testa za dolocanje za prostato specificnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugace ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate vseeno že dosegli. .Tudi casovne spremembe v pojavljanju raka debelega crevesa in danke je potrebno ocenjevati ob upoštevanju sprememb v diagnostiki – leta 2009 smo namrec v Sloveniji uvedli Državni pro- gram presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem crevesu in danki (Svit). Groba incidencna stopnja raka debelega crevesa in danke pri moških od leta 2009 pada za 2,7 % letno, pred tem pa je narašcala vsako leto za 5,2 %. Povprecne letne odstotne spremembe so prikazane ob krivuljah na Sliki 7a. .Med pogostejšimi rakavimi boleznimi pri ženskah so se vecale grobe incidencne stopnje rakadojk (za 2,4 % povprecno letno), kože, razen melanoma (povecanje za povprecno 5,7 % letno), pljucnega raka (za povprecno 5,9 % letno) in raka maternicnega telesa (za povprecno 2,1 % letno). .Incidencna stopnja raka maternicnega vratu od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na maternicnem vratu (ZORA) strmo pada (za povprecno 3,6 % na leto v zadnjih desetih letih). .Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa Svit leta 2009 spreminja casovni trend pojavljanja raka debelega crevesa in danke – po letu 2009 groba inci- dencna stopnja pada za 2,5 % letno, pred tem pa je narašcala vsako leto za 5,2 %. 180 160 140 120 100 80 60 40 20 0 Groba stopnja na 100.000Crude rate per 100,000 +1,4* % -2,7* % -0,4 % -1,6* % +5,6* % +1,5* % +2,3* % +3,7* % MoškiMales 180 160 140 120 100 80 60 40 20 0 Groba stopnja na 100.000Crude rate per 100,000 +1,4* % -2,7* % -0,4 % -1,6* % +5,6* % +1,5* % +2,3* % +3,7* % MoškiMales 19501955196019651970197519801985199019952000200520102015 2018 Pljuca / Lung (C33–C43) Prostata / Prostate (C61) Leto / Year Koža, razen melanoma / Skin, non-melanoma (C44) Glava in vrat / Head and neck (C00–C14, C30–C32) Debelo crevo in danka / Colorectum (C18–C20) Želodec / Stomach (C16) Mehur / Bladder (C67) Koža, melanom / Skin, melanoma (C43) * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 7a. Groba letna incidencna stopnja izbranih rakov s povprecno letno spremembo v zadnjih 10 letih pri moških, Slovenija 1950–2018. Figure 7a. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years inmales, Slovenia 1950-2018. Dojka / Breast (C50) Koža, razen melanoma / Skin, excl. melanoma (C44) Leto / Year Debelo crevo in danka / Colorectum (C18–C20) Pljuca / Lung (C43) Maternicno telo / Corpus uteri (C54) Koža, melanoma / Skin, melanoma (C43) Maternicni vrat / Cervix uteri (C53) Želodec / Stomach (C16) * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 7b. Groba letna incidencna stopnja izbranih rakov s povprecno letno spremembo v zadnjih 10 letih pri ženskah, Slovenija 1950–2018. Figure 7b. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years infemales, Slovenia 1950-2018. Redki raki . Poseben izziv so redke rakave bolezni (opredeljene kot tiste, ki se jih letno diagnosticira manj kot6 novih primerov na 100.000 prebivalcev). . Skupaj so redki raki v Sloveniji predstavljali približno petino vseh novo ugotovljenih primerov raka – letno je za njimi zbolelo okrog 3.000 bolnikov. . Za redke rake je znacilno, da se v primerjavi s pogostejšimi veckrat pojavljajo pri otrocih in mladostnikih. . Kot pri vseh redkih boleznih so tudi pri redkih rakih spopadamo s podobnimi težavami: pozno intežko jih diagnosticiramo, njihov nastanek in možnosti zdravljenja so slabo raziskani ali pa najustreznejše zdravljenje ni dostopno. Da bi uspešno obvladovali redke rake, je pomembno, da njihovobreme natancno spremljamo, ter da vse države sprejmejo smernice in dolocijo referencne centreza diagnostiko in zdravljenje teh bolnikov. Slika 8: Odstotni delež redkih, pogostih in nerazvršcenih rakov po starostnih skupinah, Slovenija 2004-2013. Figure 8: Percentage distribution of rare, common and unclassified cancers by agegroup, Slovenia 2004-2013. Nerazvršcen / UnclassifiedPogosti / CommonRedki / Rare 100 90 80 70 60 50 40 30 20 10 0 % 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000200520102015 2018 180 160 140 120 100 80 60 40 20 0 Groba stopnja na 100.000Crude rate per 100,000 +2,4* % -2,5* % +2,1* % -1,4* % +5,7* % +5,9* % -3,6* % +1,4* % ŽenskeFemales Age / Starost 0–45–9 10–1415–19 20–2425–29 30–3435–39 40–44 45–4950–54 55–5960–64 65–6970–74 75–7980+ Vsi / All Preživetje . Petletno cisto preživetje moških bolnikov s katerokoli vrsto raka razen nemelanomskega kožnega, ki so zboleli v obdobju 2014–2018, je bilo že 57,3 %, pri ženskah pa 61,0 %. . Vec kot 80 % je bilo cisto 5-letno preživetje pri moških z rakom mod, prostate, šcitnice in kožnim melanomom, pri ženskah pa pri bolnicah z rakom šcitnice, kožnim melanomom, rakom dojk, Hodgkinovo boleznijo in rakom maternicnega telesa. . V letu 2020 je bil narejen pregled preživetij slovenskih onkoloških bolnikov, zbolelih med letoma 1997 in 2016. Rezultati analize so na voljo v publikaciji Preživetje bolnikov z rakom, zbolelih v letih 1997–2016 v Sloveniji (Zadnik at al, 2020), ki je v digitalni obliki dostopna na www.onko-i.si/rrs. Glavni zakljucki so: 1. Preživetje slovenskih bolnikov z rakom se s casom povecuje. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno cisto preživetje povecalo za 11 odstotnih tock. Obcutno vecja je rast pri moških, kjer se je petletno cisto preživetje povecalo za 17 odstotnih tock (iz 38 % na 55 %). Pri ženskah je petletno cisto preživetje zraslo za 6 odstotnih tock (iz 54 % na 60 %). 2. Kljucna dejavnika za preživetje bolnikov z rakom sta še vedno starost in stadij ob diagnozi. Petletno cisto preživetje je najmanjše pri starejših od 75 let, vendar se je tudi v skupini najstarejših bolnikov v zadnjih 20 letih petletno preživetje izboljšalo za 7 odstotnih tock. Petletno cisto preživetje bolnikov z omejenim stadijem se je v 20 letih povišalo za 10 odstotnih tock; preživetje pri bolnikih z razsejanim stadijem se ne izboljšuje. 3. Pri obeh spolih se je v zadnjih 20 letih znacilno povecalo preživetje pri treh pogostih rakih: raku na debelem crevesu in danki (za 14 odstotnih tock iz 48 % na 62 %), kožnem melanomu (za 12 odstotnih tock iz 79 % na 91 %) ter pri pljucnem raku (za 8 odstotnih tock iz 10 % na 18 %). Rezultati odražajo zgodnejšo diagnostiko in napredek pri sistemskem zdravljenju. 4. Obcuten je tudi napredek pri obeh najpogostejših rakih, raku dojke pri ženskah in raku prostate pri moških: petletno cisto preživetje bolnic z rakom dojke se je v zadnjih 20 letih povecalo za 10 odstotnih tock, petletno cisto preživetje bolnikov z rakom prostate pa celo za vec kot 20 odstotnih tock. Velik napredek pri raku prostate je verjetno samo navidezen, saj smo ravno v obravnavnem obdobju v Sloveniji precej nekriticno uporabljali testiranje PSA, s katerim smo odkrivali rake prostate, ki bi po naravnem poteku še dolgo ostali klinicno nemi ter tako s predhodno diagnozo umetno podaljšali preživetje. 5. V skupino rakov, kjer napredka s casom ni opaziti ter pri katerih preživetje še vedno ostajaja slabo, pa sodijo rak trebušne slinavke, rak požiralnika, raki jeter, žolcnika in žolcevodov ter možganski tumorji. 6. V raziskavi CONCORD-3 smo primerjali petletna cista preživetja odraslih bolnikov s petnajstimi razlicnimi vrstami raka, zbolelimi med letoma 2010 in 2014 v 26 evropskih državah. Preživetje slovenskih bolnikov z rakom je v vecini primerov pod evropskim povprecjem, kar nam daje dobro osnovo za nadaljnje izboljšave. 7. Med bolniki z rakom je manj kot 1 % otrok in mladostnikov; zbolevajo predvsem za levkemijami, tumorji osrednjega živcevja in limfomi in imajo boljše petletno preživetje kot odrasli. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno preživetje otrok in mladostnikov, zbolelih za rakom, povecalo za 7 odstotnih tock (iz 79 % na 86 %). Modo Testis Prostata Prostate Koža, melanom Skin, melanoma Šcitnica Thyroid gland Hodgkinov limfom Hodgkin’s lymphoma Limfaticna levkemija Lymphocytic leukaemia Kosti Bone Ledvica z ledvicnim mejom Kidney with renal pelvis Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma Grlo Larynx Debelo crevo Colon Secni mehur Bladder Vezivno in mehko tkivo Connective and soft tissue Usta Mouth Levkemije, drugo Leukaemias, other Žrelo Pharynx Želodec Stomach Sapni, sapnici in pljuca Trachea, bronchus and lung Požiralnik Oesophagus Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts Trebušna slinavka Pancreas Vsi raki, razen kožnega All cancer sites excl. skin Moški Males C43 C61 C33–C34 C40–C41 C32 C67 C18 C10–C14 C25 C19–C20 C00–C96 brez C44 C62 C73 C81 C91 C64–C65 C82–C85 C48–C49 C00–C09 C92–C95 C16 C15 C22 20 400 60 80 100 Preživetje je vec kot 50 % (62,0 % vseh ugotovljenihrakov v 2014–2018) Preživetje je manj kot 50 % (28,0 % vseh ugotovljenih rakov v 2014–2018) 96,8 97,9 94,1 90,4 90,6 85,6 90,0 91,8 79,8 89,4 75,3 63,5 67,7 60,6 67,2 66,8 64,3 62,4 64,2 69,4 64,0 67,1 61,4 63,0 56,0 55,9 55,9 59,5 53,6 52,3 34,7 30,2 30,6 29,3 29,9 28,1 17,9 13,2 10,3 9,1 10,0 8,1 5,7 4,7 57,3 55,4 10 30507090% 2014–2018 2009–2013 Slika 9a. Petletno cisto preživetje (s 95 % intervalom zaupanja) pri moških, zbolelih za izbranimi raki v letih 2014–2018 in 2009-2013. Figure 9a. Five-year net survival (with 95% confidence interval) for malesdiagnosed with selected cancers in periods 2014–2018 and 2009–2013. Šcitnica Thyroid gland Koža, melanom Skin, melanoma Dojka Breast Hodgkinov limfom Hodgkin’s lymphoma Maternicno telo Corpus uteri Usta Mouth Maternicni vrat Cervix uteri Ledvica z ledvicnim mehom Kidney with renal pelvis Limfaticna levkemija Lymphocytic leukaemia Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma Debelo crevo Colon Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction Vezivno in mehko tkivo Connective and soft tissue Kosti Bone Secni mehur Bladder Jajcnik Ovary Levkemije, drugo Leukaemias, other Žrelo Pharynx Želodec Stomach Sapni, sapnici in pljuca Trachea, bronchus and lung Požiralnik Oesophagus Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts Trebušna slinavka Pancreas Vsi raki, razen kožnega All cancer sites excl. skin Ženske Females C50 C43 C33–C34 C53 C18 C40–C41 C19–C20 C10-C14 C25 C91 C00–C96 brez C44 C73 C81 C54 C00–C09 C64–C65 C82–C85 C67 C56 C92–C95 C16 C15 C22 More than 50 % survival (62,9 % of all cancers diagnosedin 2014–2018) Less than 50 % survival (24,2 % of all cancers diagnosed in 2014–2018) C48–C49 96,8 95,5 61,0 59,0 91,3 89,6 87,3 86, 84,7 85,3 80,2 80,1 70,1 64,5 69,6 69,0 64,6 64,8 64,4 65,0 63,6 65,5 62,9 60,9 59,9 58,4 57,0 46,4 50,5 62,4 47,5 43,4 41,4 41,8 39,7 38,5 38,5 45,9 32,0 28,1 26,2 19,1 15,2 11,4 12,9 4,3 8,1 4,7 0 10 20 30 40 50 60 70 80 90100% 2014–2018 2009–2013 Slika 9b. Petletno cisto preživetje (s 95 % intervalom zaupanja) pri ženskah, zbolelih za izbranimi raki v letih 2014–2018 in 2009-2013. Figure 9b. Five-year net survival (with 95% confidence interval) for females diagnosed with selected cancers in periods 2014–2018 and 2009–2013. Primerjava z Evropo . Po ocenah Evropskega informacijskega sistema za raka (https://ecis.jrc.ec.europa.eu/) je bila Slovenija leta 2020 po incidencni stopnji (starostno standardizirani na evropsko prebivalstvo) vseh rakov razen kožnega (616/100.000) na osmem mestu med 27 evropskimi državami. Višjo incidenco so imele Irska, Danska, Nizozemska, Belgija, Ciper, Madžarska in Francija. . Po umrljivostni stopnji smo na sedmem mestu, pred nami so Slovaška, Poljska, Ciper, Madžarska, Hrvaška in Danska. 458,0–510,1 510,1–562,1 562,1–614,2 614,2–666,2 666,2–718,3 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2020 EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2020 Ocena incidence po državahEstimated incidence by country Vir: ECIS - Evropski informacijski sistem za rakahttps://ecis.jcr.ec.europa.eu Source: ECIS - European Cancer Information System Slika 10a. Ocenjena starostno standardizirana (evropski standard) incidencna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020. Figure 10a. Estimated age-standardized (European standard) incidence rates of cancer (excluding non-melanoma skin) in Europe, 2020. 213,9–241,5 241,5–268,0 269,0–296,6 296,6–324,1 324,1–351,7 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 Ocena umrljivosti po državahEstimated mortality by country EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2020 EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2020 213,9–241,5 241,5–268,0 269,0–296,6 296,6–324,1 324,1–351,7 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 Ocena umrljivosti po državahEstimated mortality by country EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2020 EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2020 Vir: ECIS - Evropski informacijski sistem za rakahttps://ecis.jcr.ec.europa.eu Source: ECIS - European Cancer Information System Slika 10b. Ocenjena starostno standardizirana (evropski standard) umrljivostna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020. Figure 10b. Estimated age standardized (European standard) mortality rates of cancer (excluding non-melanoma skin) in Europe, 2020. Cancer in Slovenia28Cancer in Slovenia For additional information on the burden of cancer in Slovenia and in the world, visit: www.slora.si. Figures are available on pages 15–27. Basic figures on cancer in Slovenia 2018 .In 2018, 15,905 people (8,515 men and 7,390 women) were diagnosed with cancer in Slovenia. .The age-standardized incidence rate (European standard population) was 502.3/100,000; 584.4 in men and 444.5 in women. Among those born in 2018, one in two men and one in three wom- en are expected to develop cancer by the age of 75. .In 2018, 6,548 Slovenians died of cancer, 3,593 men and 2,955 women. There were 116,507 people alive in Slovenia (53,522 men and 62,985 women) who had at some point during their lifetime been diagnosed with cancer (prevalence). .There are no significant differences in the burden of cancer between regions of Slovenia. Age of patients .Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2018, as many as 66% men and 62% women were diagnosed with cancer after the age of 65. Less than half a percent of all cancers were diagnosed in children and adolescents (up to 20 years of age). .Among those born in 2018, one in two men and one in three women are expected to de- velop cancer by the age of 75. .Every year around 15,000 Slovenians (almost 8,000 men and more than 7,000 women) are diagnosed with cancer and more than 6,500 (about 3,500 men and 3,000 women) die of cancer. Currently, there are already over 110,000 people living in Slovenia, who have at some point during their lifetime been diagnosed with cancer (prevalence). .The risk of developing cancer increases gradually with age and is highest among the elder- ly population; of all cancer patients diagnosed in 2018, 64% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people. .In 2018, the most frequent cancers in Slovenia (skin, prostate, lung, breast and colorectal) accounted for 61% of all diagnosed cancers. These cancers are associated with unhealthylifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consum- ption – primary prevention measures should be in place with the aim to reduce their burden. .Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia are expected to lower mortality from breast, colo- rectal and cervical cancer through early detection; for colorectal and cervical cancer, a reduction in cancer incidence is also expected. .The five-year net survival of adult Slovenian patients with any type of cancer (excludingnon-melanoma skin cancer) who were diagnosed in the 2014–2018 period was 57% in menand 61% in women. Summary28Cancer in Slovenia For additional information on the burden of cancer in Slovenia and in the world, visit: www.slora.si. Figures are available on pages 15–27. Basic figures on cancer in Slovenia 2018 .In 2018, 15,905 people (8,515 men and 7,390 women) were diagnosed with cancer in Slovenia. .The age-standardized incidence rate (European standard population) was 502.3/100,000; 584.4 in men and 444.5 in women. Among those born in 2018, one in two men and one in three wom- en are expected to develop cancer by the age of 75. .In 2018, 6,548 Slovenians died of cancer, 3,593 men and 2,955 women. There were 116,507 people alive in Slovenia (53,522 men and 62,985 women) who had at some point during their lifetime been diagnosed with cancer (prevalence). .There are no significant differences in the burden of cancer between regions of Slovenia. Age of patients .Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2018, as many as 66% men and 62% women were diagnosed with cancer after the age of 65. Less than half a percent of all cancers were diagnosed in children and adolescents (up to 20 years of age). .Among those born in 2018, one in two men and one in three women are expected to de- velop cancer by the age of 75. .Every year around 15,000 Slovenians (almost 8,000 men and more than 7,000 women) are diagnosed with cancer and more than 6,500 (about 3,500 men and 3,000 women) die of cancer. Currently, there are already over 110,000 people living in Slovenia, who have at some point during their lifetime been diagnosed with cancer (prevalence). .The risk of developing cancer increases gradually with age and is highest among the elder- ly population; of all cancer patients diagnosed in 2018, 64% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people. .In 2018, the most frequent cancers in Slovenia (skin, prostate, lung, breast and colorectal) accounted for 61% of all diagnosed cancers. These cancers are associated with unhealthylifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consum- ption – primary prevention measures should be in place with the aim to reduce their burden. .Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia are expected to lower mortality from breast, colo- rectal and cervical cancer through early detection; for colorectal and cervical cancer, a reduction in cancer incidence is also expected. .The five-year net survival of adult Slovenian patients with any type of cancer (excludingnon-melanoma skin cancer) who were diagnosed in the 2014–2018 period was 57% in menand 61% in women. Summary . As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people. We estimate that in 2021, there will have been as many as 17,170 newly diagnosed cancer patients. Time trends . In general, the crude incidence and mortality rates of cancer are increasing. . The crude incidence rate has almost doubled in the last twenty years, increasing by an average of 2.1% per year over the last decade (by 1.9% in men and 2.5% in women). The crude mortality rate has increased on average by 1.1% per year in men over the last 10 years and by 1.3% in women. . More than half of this increase can be attributed to an ageing population, as longer life ex- pectancy means more people are likely to be diagnosed with cancer. The age-standardized, cumulative incidence rate shows that the risk of cancer adjusted for ageing has been increasing more slowly, with the trend reversed for men. It is also encouraging that cancer mortality (if we adjust for ageing) has been declining, especially since the mid-1990s, pointing to greater successes of cancer treatment. Most frequent cancers . Cancer is not a single disease, but rather several hundred different diseases. These can occur in all tissues and organs of the human body. They vary in frequency, treatment, and outcome, and are also associated with different, more or less established risk factors. . The five most frequent cancers in Slovenia – skin (excluding melanoma), prostate, lung, breast and colorectal – account for 61% of all new cancer cases. . The most frequent cancers are associated with an unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consumption. Primary prevention measures should be in place with the aim to reduce their burden. . In men, prostate cancer and non-melanoma skin cancer account for one-fifth of all cancers each, followed by lung and colorectal cancer. In women, non-melanoma skin cancer is the most frequent cancer, followed by breast cancer, which accounts for one-fifth of all cancer cases. The following most frequent cancer sites in women are colorectal and lung cancer. . The most frequent cancers differ according to age. In children and adolescents aged under 20 years leukaemias are the most frequent, followed by tumours of the central and autonomic nervous system. Young adult men are most often diagnosed with testicular cancer, while in young women breast cancer is already ranked first. Time trends for most frequent cancers . Among the more frequent cancers in men, the incidence rate of lung cancer was increasing until the early 1990s, when it stabilized at around 90/100,000. . Lung cancer is outranked by the steep rising rates of prostate cancer (crude incidence rate increases at the rate of 1.4% per year on average) and non-melanoma skin cancer (an increase of 5.6% on average per year). The dramatic increase in the incidence of prostate cancer over the past decade is not due to any newly identified risk factor, but rather to the increasing use of the prostate-specific antigen (PSA) test in healthy men and therefore detection of a large number of cancers that would have otherwise remained undetected for life. Data for recent years indicate that we have already reached the peak incidence of prostate cancer. . Time trends in the incidence of colorectal cancer must also be interpreted by taking into accountchanges in diagnostics – in 2009 Slovenia introduced the national screening and early detectionprogramme for colorectal cancer (Svit). The crude incidence rate of colorectal cancer in men decreased by 2.7% per year from 2009 on, but it was on the rise the years before (5.2% on averageannually). Average annual percentage changes are shown next to the incidence curves in Figure 7. . Among the more frequent cancers in women, crude incidence rates have been increasing for breast cancer (by 2.4% on average per year), skin, excluding melanoma (by 5.7% on average per year), lung cancer (by 5.9% on average per year) and uterine cancer (by 2.1% on average per year). . The incidence rate of cervical cancer has decreased significantly since the introduction of the national cervical cancer screening programme (ZORA) (by an average of 3.6% per year in the last ten years). . Similar to men, the introduction of the Svit screening programme in 2009 has had an impact on the time trend of colorectal cancer in women – the crude incidence rate of colorectal cancer in women decreased by 2.5% per year from 2009 on, but it was on the rise all the years before (5.2% on average annually). Rare cancers . A particular challenge is posed by rare cancers (defined as those with less than six new cases per 100,000 per year). . In total, rare cancers in Slovenia accounted for about a fifth of all newly diagnosed cancers – around 3,000 patients were diagnosed with rare cancers every year. . As opposed to frequent cancers, rare cancers are more likely to occur in children and adolescents. . Problems with rare cancers are similar to those characteristic of all rare diseases: they are difficult to diagnose and are often detected late, their aetiology and treatment options are poorly researched, or else the most appropriate treatment is hard to access. In order to successfully manage rare cancers, it is important that their burden is closely monitored, and that all countries adopt guidelines as well as establish reference centres for diagnostics and treatment of such patients. Survival . The five-year net survival of male patients with any type of cancer excluding non-melanoma skin cancer diagnosed between 2014 and 2018 was 57.3%, while in women it was 61.0%. . The five-year net survival was over 80% in men with testicular cancer, prostate cancer, thyroid cancer and skin melanoma, and in women with thyroid cancer, skin melanoma, breast cancer, Hodgkin's disease and uterine cancer. . In 2020, a survival analysis of Slovenian cancer patients diagnosed between 1997 and 2016 was performed. The results of the analysis are published in the publication Survival of cancer patients, diagnosed in 1997–2016 in Slovenia (Zadnik et al, 2021) which is also available in digital format at www.onko-i.si/eng/crs. Main conclusions are on the next page. 1. Survival of Slovenian cancer patients is improving over time. During the 20 years observed (1997–2001 and 2012–2016), five-year net survival increased by 11 percentage points. The increase was significantly higher in men, for whom five-year net survival increased by 17 percentage points (from 38% to 55%). In women, five-year net survival increased by 6 percentage points (from 54% to 60%). 2. Age and stage at diagnosis are still key factors when it comes to survival of cancer patients. Five-year net survival is lowest in those aged 75–94, though even in this age group it has improved by 7 percentage points over the past 20 years. Five-year net survival of patients with localized disease increased by 10 percentage points over the observed 20 years and has reached 85% during the last period; survival of patients with distant disease has not improved. 3. For both sexes combined, survival has improved significantly over the last 20 years for the three most frequent cancers: colorectal cancer (by 14 percentage points, from 48% to 62%), skin melanoma (by 12 percentage points, from 79% to 91%), and lung cancer (by 8 percentage points, from 10% to 18%). This improvement is due to earlier diagnosis and advances in systemic treatment. 4. Progress has also been shown in the two most frequent cancers by sex: breast cancer in women and prostate cancer in men. The five-year net survival of breast cancer patients has increased by 10 percentage points in the last 20 years, while the five-year net survival of prostate cancer patients has increased for over 20 percentage points. The improvement in prostate cancer survival is probably not real, since in the period under review, PSA testing in Slovenia was performed rather uncritically and likely resulted in detection of prostate cancers that would have otherwise remained clinically silent for a long time, thus artificially prolonging survival on account of earlier diagnosis in the natural course of disease. 5. The group of cancers where no progress has been observed over time and where survival still remains low includes pancreatic cancer, oesophageal cancer, liver, gallbladder and bile duct cancers as well as brain tumours. 6. In the CONCORD-3 study, five-year net survival of adult patients with 15 different cancers diagnosed between 2010 and 2014 was compared among 26 European countries. In most cases survival rates of Slovenian cancer patients are below the European average, which highlights the need and serves as an incentive for future improvements. 7. Less than 1% of cancer patients are children and adolescents; they are mainly diagnosed with leukaemias, central nervous system tumours and lymphomas, and have a better five- year survival compared to adults. In the last 20 years (1997–2001 and 2012–2016), the five- year survival of children and adolescents with cancer has increased by 7 percentage points (from 79% to 86%). Comparisons with Europe . In 2020, according to the estimates of the European Cancer Information System (https://ecis. jrc.ec.europa.eu/) Slovenia ranked eighth among 27 European countries with respect to the incidence rate (age standardized, European population standard) of all cancers excluding skin cancer (616/100,000). Ireland, Denmark, the Netherlands, Belgium, Cyprus, Hungary and France had a higher incidence. . We are in seventh place in terms of mortality, led by Slovakia, Poland, Cyprus, Hungary, Croatia and Denmark. Incidenca Incidence Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2009-2018 in 2021. Table 1: Observed and estimated cancer incidence by sex, Slovenia 2009-2018 and 2021. Šifra Primarna Spol Povprecne letne opazovane vrednosti 2009-2013 Povprecne letne opazovane vrednosti 2014-2018 Ocena za 2021 MKB lokacija Število Incidencna stopnja na 100.000 Število Incidencna stopnja na 100.000 Število s 95 % napovednim intervalom Incidencna stopnja na 100.000 s 95 % napovednim intervalom ICD Primary Sex Average annual observed values 2009-2013 Average annual observed values 2014-2018 Estimation for 2021 code site Number Incidence rate per 100,000 Number Incidence rate per 100,000 Number with 95% prediction interval Incidence rate per 100,000 with 95% prediction interval C00- C96 Vse lokacije All sites M+Ž M Ž 13532 7394 6138 659,4 727,8 592,4 15116 8172 6944 732,0 797,3 667,6 17170 16813-17527 9173 8910-9436 7997 7755-8238 814 797-831 865 841-890 762 739-785 C00- Usta in žrelo M 275 27,0 274 26,8 265 223-308 25 21-29 C14 Mouth and pharynx Ž 73 7,0 81 7,7 82 59-106 8 6-10 C15 Požiralnik Oesophagus M Ž 69 16 6,8 1,5 75 18 7,3 1,7 74 52-97 19 7-30 7 5-9 2 1-3 C16 Želodec Stomach M Ž 297 186 29,2 17,9 277 171 27,1 16,5 260 218-301 160 128-193 24 21-28 15 12-18 C18 Debelo crevo Colon M Ž 527 396 51,9 38,3 481 368 46,9 35,4 460 400-520 358 305-410 43 38-49 34 29-39 C19 Rektum in rektosigmoidna zveza M 418 41,1 346 33,7 287 245-330 27 23-31 -C20 Rectum and rectosigmoid junction Ž 237 22,9 197 19,0 159 128-191 15 12-18 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 131 48 12,9 4,6 166 65 16,2 6,2 219 177-260 79 54-103 21 17-25 7 5-10 C23 Žolcnik in žolcevodi M 69 6,8 92 9,0 115 85-145 11 8-14 -C24 Gallbladder and billiary tract Ž 104 10,0 104 10,0 99 73-125 9 7-12 C25 Trebušna slinavka Pancreas M Ž 171 175 16,9 16,9 210 197 20,5 18,9 252 209-296 211 172-250 24 20-28 20 16-24 C32 Grlo Larynx M Ž 92 13 9,1 1,3 91 11 8,9 1,1 90 65-115 12 3-20 8 6-11 1 0-2 C33 Sapnik, sapnici in pljuca M 862 84,9 950 92,7 1016 926-1106 96 87-104 -C34 Trachea, bronchus and lung Ž 394 38,0 527 50,6 701 618-784 67 59-75 C43 Maligni melanom kože Malignant melanoma of skin M Ž 254 252 25,0 24,3 303 266 29,5 25,6 366 313-418 290 245-336 34 30-39 28 23-32 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1174 1185 115,5 114,4 1514 1525 147,7 146,6 2011 1885-2137 2040 1923-2158 190 178-202 194 183-206 C48 Vezivno in mehko tkivo M 29 2,9 32 3,1 35 23-47 3 2-4 -C49 Connective and soft tissue Ž 38 3,7 42 4,1 46 28-64 4 3-6 C50 Dojka Breast M Ž 13 1243 1,3 119,9 11 1397 1,1 134,3 13 3-24 1578 1471-1685 1 0-2 150 140-161 C53 Maternicni vrat Cervix uteri M Ž - 131 - 12,7 - 110 - 10,6 - - 100 74-125 - - 9 7-12 C54 Maternicno telo Corpus uteri M Ž - 313 - 30,2 - 356 - 34,2 - - 390 337-443 - - 37 32-42 C56 JajcnikOvary M Ž - 161 - 15,6 - 149 - 14,3 - - 140 110-170 - - 13 10-16 C61 Prostata Prostate M Ž 1536 - 151,2 - 1652 - 161,2 - 1789 1676-1902 - - 169 158-179 - - C62 Modo Testis M Ž 101 - 9,9 - 115 - 11,2 - 124 94-154 - - 12 9-15 - - C64 Ledvica z ledvicnim mehom M 249 24,5 268 26,1 304 257-351 29 24-33 -C65 Kidney with renal pelvis Ž 123 11,8 137 13,1 150 117-183 14 11-17 C67 Secni mehur Bladder M Ž 229 84 22,5 8,1 256 97 25,0 9,4 296 251-342 111 83-140 28 24-32 11 8-13 C70 Centralni in avtonomni živcni sistem M 81 8,0 107 10,5 130 98-162 12 9-15 -C72 Central and autonomic nervous system Ž 68 6,5 72 7,0 75 57-94 7 5-9 C73 Šcitnica Thyroid gland M Ž 41 114 4,0 11,0 47 154 4,6 14,8 58 37-79 185 147-223 6 4-7 18 14-21 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 24 25 2,4 2,4 28 27 2,7 2,6 27 13-41 26 12-39 3 1-4 2 1-4 C82 Ne-Hodgkinovi limfomi M 174 17,1 224 21,9 275 224-326 26 21-31 -C85 Non-Hodgkin’s lymphoma Ž 173 16,7 204 19,6 247 203-290 23 19-28 C90 Difuzni plazmocitom in maligne neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 69 70 6,8 6,8 77 61 7,5 5,9 87 62-112 59 39-79 8 6-11 6 4-8 C91 Levkemije M 170 16,7 193 18,8 211 172-251 20 16-24 -C95 Leukaemias Ž 127 12,2 143 13,8 157 123-191 15 12-18 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2018. Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2018. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število Number Groba incidencna stopnja na 100.000 Crude incidence rate per 100,000 SSS* - svetovni standard ASR* - World standard SSS* - evropski standard ASR* - European standard SSS* - slovenski standard ASR* - Slovenian standard C00-C96 Vse lokacije All sites M+Ž M Ž 15905 8515 7390 768,3 826,5 710,7 352,1 399,0 318,8 502,3 584,4 444,5 598,8 708,7 521,6 C00-C14 Usta in žrelo Mouth and pharynx M Ž 271 68 26,3 6,5 14,2 2,9 19,5 4,1 22,1 4,7 C15 Požiralnik Oesophagus M Ž 86 17 8,3 1,6 4,1 0,4 5,9 0,7 7,0 0,8 C16 Želodec Stomach M Ž 264 174 25,6 16,7 11,7 5,9 17,7 9,0 21,8 10,8 C18 Debelo crevo Colon M Ž 482 368 46,8 35,4 21,0 13,8 32,1 20,1 40,1 24,4 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 329 170 31,9 16,3 15,4 7,0 22,7 9,9 27,3 11,8 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 166 65 16,1 6,3 7,8 2,3 11,3 3,3 13,6 4,2 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 102 88 9,9 8,5 4,3 2,8 6,7 4,2 8,4 5,2 C25 Trebušna slinavka Pancreas M Ž 234 194 22,7 18,7 10,4 6,9 15,6 10,3 19,1 12,7 C32 Grlo Larynx M Ž 104 15 10,1 1,4 5,2 0,6 7,4 0,9 8,4 1,0 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung M Ž 978 587 94,9 56,5 45,5 25,0 66,2 35,6 79,4 41,9 C43 Maligni melanom kože Malignant melanoma of skin M Ž 320 284 31,1 27,3 16,1 15,4 23,0 20,0 27,3 23,2 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1738 1865 168,7 179,4 74,7 68,3 116,0 100,3 145,1 121,5 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 40 34 3,9 3,3 2,3 2,2 3,0 2,5 3,5 2,7 C50 Dojka Breast M Ž 11 1515 1,1 145,7 0,4 75,1 0,7 102,1 0,9 116,4 C53 Maternicni vrat Cervix uteri M Ž - 108 - 10,4 - 6,8 - 8,5 - 9,4 C54 Maternicno telo Corpus uteri M Ž - 351 - 33,8 - 15,8 - 22,3 - 25,4 C56 JajcnikOvary M Ž - 142 - 13,7 - 6,9 - 9,4 - 10,9 C61 Prostata Prostate M Ž 1680 - 163,1 - 76,1 - 113,0 - 139,2 - C62 Modo Testis M Ž 86 - 8,3 - 7,4 - 8,1 - 8,7 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 306 137 29,7 13,2 14,7 5,4 21,3 7,7 25,2 9,4 C67 Secni mehur Bladder M Ž 252 90 24,5 8,7 10,9 2,9 16,7 4,3 20,7 5,2 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 105 63 10,2 6,1 7,1 4,3 8,6 4,7 9,5 4,8 C73 Šcitnica Thyroid gland M Ž 56 138 5,4 13,3 3,6 9,7 4,6 11,6 5,1 12,8 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 22 29 2,1 2,8 1,9 2,8 2,1 2,9 2,3 3,0 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne M Ž 226 198 21,9 19,0 12,1 8,2 16,5 11,6 19,0 13,8 C90 neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 76 66 7,4 6,3 3,5 2,2 5,2 3,3 6,3 4,2 C91-C95 Levkemije Leukaemias M Ž 201 150 19,5 14,4 10,0 7,0 14,1 8,9 16,8 10,1 * SSS - starostno standardizirana incidencna stopnja na 100.000 ASR - age standardized incidence rate per 100,000 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2018. Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2018. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ C00 - C96 Vse lokacije All sites M+Ž M Ž 15905 8515 7390 22 9 13 11 8 3 14 7 7 24 14 10 33 18 15 71 32 39 122 43 79 246 77 169 373 135 238 550 212 338 870 411 459 1292 708 584 2086 1238 848 2614 1599 1015 2086 1220 866 2263 1297 966 1700 868 832 1528 619 909 768,3 826,5 710,7 41,2 47,3 35,9 C00 Ustnica Lip M Ž 24 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 4 0 3 2 3 1 3 4 8 3 2,3 1,1 0,1 0,0 C01 Baza jezika Base of tongue M Ž 26 4 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 2 0 3 0 1 1 6 1 8 1 1 0 1 0 2 0 0 0 2,5 0,4 0,2 0,0 C02 Jezik, drugi deli Tongue, other & unspecified parts M Ž 22 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 2 1 6 2 7 2 1 2 2 1 1 0 1 1 2,1 0,9 0,1 0,1 C03 Dlesen Gum M Ž 5 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 1 0 1 1 2 0 0 0 0 1 2 1 0 0 3 0,5 1,0 0,0 0,0 C04 Ustno dno Floor of mouth M Ž 27 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 7 2 9 0 5 0 1 0 1 0 1 1 0 0 2,6 0,3 0,2 0,0 C05 Nebo Palate M Ž 16 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 2 0 2 0 3 0 2 0 2 0 2 1 0 0 1,6 0,1 0,1 0,0 C06 Usta, drugi deli Mouth, other & unspecified parts M Ž 10 6 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 4 0 0 0 1 0 2 0 2 1 0 1 0 0 1 2 0 1 1,0 0,6 0,1 0,0 C07 Parotidna žleza Parotid gland M Ž 8 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 2 0 1 1 0 1 1 0 1 1 0 0 0 0 0 1 2 0 0,8 0,6 0,0 0,0 Druge in neopredeljene velike C08 žleze slinavke Other & unspecified major salivary M Ž 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0,0 0,0 0,0 glands C09 Tonzila Tonsil M Ž 42 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 0 6 2 7 1 9 1 8 3 4 0 3 1 1 0 0 0 4,1 0,8 0,3 0,0 C10 Orofarinks Oropharynx M Ž 32 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 7 0 9 0 9 1 1 1 1 0 3 0 0 0 3,1 0,3 0,2 0,0 C11 Nazofarinks Nasopharynx M Ž 6 4 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 1 0 2 1 0 1 0 0 0 0 0 0 1 0 0,6 0,4 0,0 0,0 C12 Piriformni sinus Pyriform sinus M Ž 36 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 6 0 5 0 10 0 6 0 5 0 2 0 0 0 0 0 3,5 0,1 0,3 0,0 C13 Hipofarinks Hypopharynx M Ž 16 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 1 0 0 1 3 0 4 1 2 0 3 0 0 0 0 0 1,6 0,2 0,1 0,0 Druga in slabo opredeljena mesta na ustnici, v ustni votlini C14 in farinksu Other and ill-defined sites M Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 0,0 0,0 in the lip, oral cavity and pharynx C15 Požiralnik Oesophagus M Ž 86 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 3 0 4 0 5 1 20 1 24 0 10 0 9 3 4 5 6 6 8,3 1,6 0,5 0,0 C16 Želodec Stomach M Ž 264 174 0 0 0 0 0 0 0 0 0 0 1 0 0 0 3 4 5 0 9 4 9 5 22 23 30 12 40 15 37 20 38 31 47 29 23 31 25,6 16,7 1,3 0,6 C17 Tanko crevo Small intestine M Ž 30 27 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 1 1 0 6 5 1 2 7 2 4 4 5 8 2 4 3 0 2,9 2,6 0,2 0,1 C18 Debelo crevo Colon M Ž 482 368 0 0 1 0 0 0 0 0 0 1 1 0 0 3 4 4 1 9 12 10 18 18 33 19 47 38 87 48 85 58 71 47 74 50 48 63 46,8 35,4 2,5 1,7 C19 Rektosigmoidna zveza Rectosigmoid junction M Ž 66 34 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 4 3 3 6 0 6 3 10 4 9 0 6 4 11 6 7 5 7 3 6,4 3,3 0,3 0,2 C20 Rektum Rectum M Ž 263 136 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 3 3 5 14 7 20 6 19 6 49 17 40 25 29 13 45 19 29 18 13 17 25,5 13,1 1,4 0,6 C21 Anus in analni kanal Anus and anal canal M Ž 6 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 2 1 1 1 3 1 4 0 3 0 3 1 1 1 0 0 2 0,6 2,0 0,0 0,1 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 166 65 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 2 0 3 4 18 0 28 6 38 10 27 10 28 13 14 12 6 8 16,1 6,3 1,0 0,3 C23 Žolcnik Gallbladder M Ž 23 37 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 2 0 0 3 6 3 3 5 3 5 6 3 8 2 8 2,2 3,6 0,1 0,1 Drugi in neopredeljeni deli C24 biliarnega trakta Billiary tract, other and unspec- M Ž 79 51 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 2 2 4 0 12 6 15 7 14 2 11 7 10 9 10 14 7,7 4,9 0,4 0,2 ified parts C25 Trebušna slinavka Pancreas M Ž 234 194 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 2 2 3 6 13 8 16 11 28 15 58 30 32 27 31 36 33 29 17 28 22,7 18,7 1,3 0,8 Nadaljevanje —> Continued —> Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Druga in slabo opredeljena mesta C26 v prebavnih organihOther and ill-defined digestive organs M Ž 5 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 0 1 0 1 0 0,5 0,3 0,0 0,0 C30 Nosna votlina in srednje uhoNasal cavity and middle ear M Ž 6 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 1 1 1 0 1 1 0 2 0 1 1 1 0,6 0,7 0,0 0,0 C31 Obnosni sinusi Accessory sinuses M Ž 6 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 2 2 0 1 2 1 1 0 0 0 1 0 1 0,6 0,8 0,0 0,0 C32 Grlo Larynx M Ž 104 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 1 0 10 0 17 3 27 3 16 5 13 1 6 1 6 2 5 0 10,1 1,4 0,7 0,1 C33 SapnikTrachea M Ž 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0,0 0,2 0,0 0,0 C34 Sapnica in pljucaBronchus and lung M Ž 978 585 0 0 0 0 0 0 0 0 0 0 1 0 1 2 5 2 5 2 9 11 34 37 91 55 199 104 253 130 137 99 121 65 76 44 46 34 94,9 56,3 6,0 3,4 C37 Timus Thymus M Ž 9 5 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 3 0 0 0 2 1 2 1 1 0 0 0 0 1 0 0 0,9 0,5 0,1 0,0 C38 Srce, mediastinum, plevraHeart, mediastinum, pleura Druga in slabo opredeljena mesta v dihalih in prsnih organih M Ž M 1 8 0 0 0 0 0 2 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 1 0 0 2 0 0,1 0,8 0,0 0,0 0,0 0,0 C39 Other and ill-defined sites in the respiratory system and intrathoracic organs Kosti, sklepni hrustanec Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C40 udov Bone and articular cartilage of limbs Kosti, sklepni hrustanec, M Ž 10 1 1 0 0 0 0 0 2 0 0 0 0 0 0 0 1 0 1 0 0 0 2 0 2 0 0 0 0 0 1 0 0 0 0 0 0 1 1,0 0,1 0,1 0,0 C41 drugjeBone and articular cartilage of other and unspecified parts M Ž 5 8 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3 0 1 2 1 0 0 0 1 0 1 0,5 0,8 0,1 0,0 C43 Maligni melanom kože Malignant melanoma of skin M Ž 320 284 0 0 0 0 0 0 0 0 2 2 3 4 5 10 7 18 13 25 19 31 35 15 24 13 38 29 43 37 27 31 51 28 28 19 25 22 31,1 27,3 1,6 1,6 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1738 1865 0 0 0 0 0 0 0 1 0 1 5 6 12 13 9 25 32 49 40 64 85 92 111 109 154 159 247 216 258 227 326 286 246 260 213 357 168,7 179,4 8,1 7,5 C45 Mezoteliom Mesothelioma M Ž 30 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 2 1 3 1 6 5 2 2 11 3 3 2 1 0 2,9 1,4 0,1 0,1 C46 Kaposijev sarkom Kaposi’s sarcoma Periferni živci in avtonomno M Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0,1 0,0 0,0 0,0 C47 živcevjePeripheral nerves and autonomic nervous system M Ž 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0,3 0,1 0,0 0,0 C48 Peritonej in retroperitonej Retroperitoneum and peritoneum M Ž 5 11 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 3 2 0 1 2 0 2 0 0 1 0 0,5 1,1 0,0 0,1 C49 Drugo vezivno in mehko tkivo Other connective and soft tissue M Ž 35 23 0 1 1 0 0 0 0 0 1 2 0 0 1 0 0 1 2 1 2 1 2 1 3 3 4 0 4 2 5 2 5 3 2 3 3 3 3,4 2,2 0,2 0,1 C50 Dojka Breast M Ž 11 1515 0 0 0 0 0 0 0 0 0 0 0 7 0 19 0 53 0 79 0 112 0 156 2 151 1 210 1 228 2 135 1 155 3 112 1 98 1,1 145,7 0,1 8,5 C51 Žensko zunanje spolovilo Vulva M Ž - 62 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 1 - 4 - 6 - 5 - 9 - 11 - 14 - 11 - 6,0 - 0,2 C52 Nožnica Vagina M Ž - 10 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 0 - 1 - 3 - 2 - 3 - 1,0 - 0,0 C53 Maternicni vrat Cervix uteri M Ž - 108 - 0 - 0 - 0 - 1 - 1 - 3 - 7 - 11 - 6 - 12 - 13 - 10 - 12 - 8 - 6 - 5 - 4 - 9 - 10,4 - 0,7 C54 Maternicno telo Corpus uteri M Ž - 351 - 0 - 0 - 0 - 0 - 0 - 1 - 1 - 3 - 11 - 11 - 26 - 57 - 54 - 55 - 40 - 43 - 36 - 13 - 33,8 - 1,9 C55 Maternica, neopredeljenoUterus, unspecified M Ž - 5 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 1 - 1 - 0 - 0 - 0 - 1 - 0 - 0 - 1 - 0,5 - 0,0 C56 JajcnikOvary Drugi in neopredeljeni ženski M Ž - 142 - 0 - 0 - 0 - 0 - 0 - 0 - 2 - 4 - 7 - 13 - 11 - 15 - 18 - 20 - 15 - 17 - 8 - 12 - 13,7 - 0,8 C57 spolni organiOther and unspecified parts of female genital organs M Ž - 39 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 0 - 2 - 2 - 5 - 4 - 8 - 7 - 4 - 4 - 2 - 3,8 - 0,2 Nadaljevanje —> Continued —> 35 Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ C58 Posteljica Placenta M Ž - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0,0 - 0,0 C60 Penis Penis M Ž 16 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 0 - 1 - 1 - 4 - 3 - 2 - 2 - 0 - 2 - 1,6 - 0,1 - C61 Prostata Prostate M Ž 1680 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 9 - 65 - 131 - 298 - 401 - 306 - 286 - 117 - 67 - 163,1 - 10,3 - C62 Modo Testis Drugi in neopredeljeni moški M Ž 86 - 1 - 0 - 0 - 1 - 4 - 10 - 8 - 18 - 18 - 13 - 3 - 5 - 3 - 2 - 0 - 0 - 0 - 0 - 8,3 - 0,6 - C63 spolni organiOther and unspecified male genital organs M Ž 4 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 0 - 0 - 0 - 1 - 1 - 1 - 0 - 0,4 - 0,0 - C64 Ledvica razen meha Kidney, excl. renal pelvis M Ž 281 118 0 1 1 0 0 1 0 0 0 0 1 1 2 1 3 1 4 3 8 2 22 1 33 11 51 10 50 18 33 21 35 20 24 17 14 10 27,3 11,3 1,6 0,6 C65 Ledvicni meh Renal pelvis M Ž 25 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 4 1 5 2 3 3 6 9 3 1 2 2 2,4 1,8 0,1 0,1 C66 Secevod Ureter M Ž 12 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 0 2 0 4 0 1 2 2 1 0 1 1,2 0,4 0,1 0,0 C67 Secni mehur Bladder Drugi in neopredeljeni secni M Ž 252 90 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 3 1 6 4 23 6 34 12 50 10 42 7 42 7 27 20 24 22 24,5 8,7 1,4 0,3 C68 organiOther and unspecified urinary organs M Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 0,2 0,1 0,0 0,0 C69 Oko in ocesni adneksi Eye and adnexa M Ž 19 18 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 0 0 1 2 1 2 0 2 4 1 3 2 4 2 4 2 1 0 0 2 1,8 1,7 0,1 0,1 C70 MeningeMeninges M Ž 2 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0,2 0,3 0,0 0,0 C71 MožganiBrain Hrbtni mozeg, možganski živci in M Ž 100 60 2 6 2 0 1 1 2 1 3 0 1 1 5 0 4 1 6 3 10 2 8 2 7 6 9 8 14 8 6 5 15 7 5 3 0 6 9,7 5,8 0,6 0,4 C72 drugi deli CŽSSpinal cord, cranial nerves and other parts of CNS M Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0,3 0,0 0,0 0,0 C73 Šcitnica Thyroid gland M Ž 56 138 0 0 0 0 0 2 0 0 1 3 2 7 1 7 4 16 6 12 11 17 3 13 10 11 5 14 4 13 3 8 5 8 0 5 1 2 5,4 13,3 0,4 0,9 C74 Nadledvicna žleza Adrenal gland Druge endokrine žleze in sorodne M Ž 8 7 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 1 0 2 0 0 0 2 1 1 3 0 0 0 0 0,8 0,7 0,1 0,0 C75 strukture Other endocrine glands and related structures M Ž 0 2 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0,0 0,2 0,0 0,0 C76 Druga in slabo opredeljena mestaOther and ill-defined sites Metastaza in neopredeljena M Ž 1 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 2 0 1 0 1 0 2 0 0 0 3 0,1 1,2 0,0 0,1 C77 maligna neoplazma bezgavkMetastasis and unspecified malignant neoplasm of lymph nodes Metastaze dihal in M Ž 15 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 0 3 2 5 1 3 1 0 2 0 4 1 1 1 2 1,5 1,4 0,1 0,1 C78 prebavilMetastases of respiratory and digestive organs M Ž 31 34 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 1 1 2 1 4 1 1 4 2 9 5 4 4 9 15 3,0 3,3 0,1 0,1 C79 Metastaze, drugjeMetastases of other sites Maligna neoplazma brez M Ž 9 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 3 2 3 0 0 1 1 4 9 0,9 1,6 0,0 0,1 C80 opredeljenega mestaMalignant neoplasm withoutspecification of site M Ž 54 58 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 3 2 12 7 11 6 8 8 5 9 7 14 6 11 5,2 5,6 0,3 0,2 C81 Hodgkinov limfomHodgkin’s lymphoma Folikularni ne-Hodgkinov M Ž 22 29 0 0 0 0 0 1 3 2 1 2 2 5 0 4 7 2 1 2 0 0 2 2 1 2 0 2 1 0 0 0 4 3 0 2 0 0 2,1 2,8 0,1 0,2 C82 limfom Follicular non-Hodgkin’s lymphoma M Ž 64 65 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 4 1 3 2 2 4 13 7 14 11 7 14 8 6 4 11 4 4 4 3 6,2 6,3 0,4 0,4 C83 Difuzni ne-Hodgkinov limfomDiffuse non-Hodgkin’s lymphoma M Ž 133 106 0 0 1 0 1 0 2 0 4 0 0 0 1 1 1 3 6 1 2 3 4 3 16 7 17 14 21 15 18 22 15 11 15 11 9 15 12,9 10,2 0,8 0,6 Nadaljevanje —> Continued —> Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Limfomi celic T in kožni limfom C84 celic T Peripheral and cutaneous T-cell lymphomas Druge in neopredeljene vrste M Ž 21 19 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1 2 1 2 0 0 2 2 2 4 1 2 2 1 1 2 2 3 3 1 3 2,0 1,8 0,1 0,1 C85 ne-Hodgkinovega limfomaOther and unspecified types ofnon-Hodgkin’s lymphoma Maligne imunoproliferativne M Ž 8 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 2 1 0 1 3 1 0 0 0 1 3 0,8 0,8 0,0 0,0 C88 bolezni Malignant immunoproliferativediseases Difuzni plazmocitom in maligne M Ž 5 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1 2 0 0 0 0 0 0 1 0,5 0,2 0,0 0,0 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms M Ž 76 66 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 3 0 5 2 10 3 6 9 12 8 11 11 12 14 9 10 6 9 7,4 6,3 0,4 0,3 C91.0 Limfoblastna levkemija Lymphoblastic leukaemia, acute M Ž 9 8 0 2 0 0 2 1 0 2 1 0 1 0 1 0 1 1 1 0 0 0 0 0 0 0 1 1 0 1 0 0 1 0 0 0 0 0 0,9 0,8 0,1 0,1 C91.1- Limfaticna levkemija, druga M 96 0 0 0 0 0 0 1 1 1 1 3 8 18 19 16 13 9 6 9,3 0,6 C91.9 Lymphoid leukaemia, other Ž 46 0 0 0 0 0 0 0 0 0 0 3 1 8 7 6 6 10 5 4,4 0,2 C92 Mieloicna levkemija Myeloid leukaemia M Ž 69 68 0 0 0 0 1 0 0 2 0 0 0 0 0 3 1 1 2 3 2 1 4 3 9 1 7 7 9 10 7 5 9 10 12 14 6 8 6,7 6,5 0,3 0,3 C93 Monocitna levkemija Monocytic leukaemia Druge opredeljene M Ž 5 5 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 0 1 2 2 0 0 0 0 0,5 0,5 0,0 0,0 C94 levkemije Other leukaemias of specified cells Levkemija z neopredeljenim M Ž 17 20 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 3 4 5 2 2 2 3 1 2 3 0 5 1 0 1,7 1,9 0,1 0,1 C95 celicnim tipomLeukaemia, unspecified cell type Druge in neopredeljene maligneneoplazme limfaticnega, krvot- M Ž 5 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 3 1 0 2 0,5 0,3 0,0 0,0 C96 vornega ali sorodnega tkivaOther and unspecified malignantneoplasms of lymphoid, haematopoietic and related tissue M Ž 92 84 1 0 2 0 0 0 0 1 0 1 0 0 0 1 2 3 1 1 2 5 2 7 4 1 7 2 12 8 12 14 22 15 15 11 10 14 8,9 8,1 0,4 0,4 Zgoraj neupoštevani: Not included above: D03 Melanom, in situ Melanoma, in situ M Ž 146 167 0 0 0 0 0 0 1 1 0 1 0 2 3 8 12 10 9 15 11 17 11 19 15 10 20 20 16 18 17 12 16 18 9 6 6 10 14,2 16,1 0,9 1,0 D05 Dojka, in situ Breast, in situ M Ž 2 169 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 0 6 0 16 0 34 0 29 0 21 0 36 1 9 1 8 0 3 0 3 0,2 16,3 0,0 1,1 D06 Maternicni vrat, in situ (CIN III) Cervix uteri, in situ M Ž - 1052 - 0 - 0 - 0 - 0 - 91 - 179 - 185 - 189 - 161 - 89 - 56 - 42 - 32 - 12 - 11 - 4 - 0 - 1 - 101,2 - 8,1 D09.0 Secni mehur, in situ Bladder, in situ Meninge, benigna neoplazma in neoplazma M Ž 221 71 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 2 4 0 8 1 16 6 18 5 31 8 45 15 37 6 27 13 14 6 17 9 21,5 6,8 1,4 0,3 D32.0, negotovega znacaja M 49 0 0 1 1 0 1 2 1 2 5 4 2 6 8 6 3 6 1 4,8 0,3 D42.0 Benign neoplasm and neoplasm of uncertain behaviour of meninges Ž 108 0 0 0 0 1 1 4 3 5 4 12 9 15 15 10 7 7 15 10,4 0,6 D33.0- Možgani, benigna neoplazma M 4 1 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0,4 0,0 D33.2 Benign neoplasm of brain Jajcnik, neoplazma Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0,1 0,0 D39.1 negotovega znacajaOvary, neoplasm of uncertain behavior M Ž - 70 - 0 - 0 - 0 - 0 - 2 - 1 - 7 - 5 - 5 - 9 - 7 - 13 - 6 - 7 - 6 - 1 - 1 - 0 - 6,7 - 0,5 D43.0- D43.2 Možgani, neopredeljenoCentral nervous system (CNS), uncertain or unknown M Ž 7 5 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 3 1 0 0 0 0 0 1 2 2 0 0,7 0,5 0,0 0,0 Tabela 4a: Incidenca mikroskopsko (histološko in citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2018. Table 4a: Incidence of microscopicaly (histologically and cytologically) confirmed cancer cases by morphological type, Slovenia 2018. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 C10 C11 C12 C13 C14 C15 C16 C17 C18 Vse vrste / All types 13961 35 29 31 15 29 17 16 14 1 50 33 10 37 18 0 91 427 56 810 Small cell carcinoma 245 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 Non-small cell carcinoma 79 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1685 35 28 31 15 29 16 16 2 0 50 31 9 35 18 0 64 1 0 0 Basal cell carcinoma 2931 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 374 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 7124 0 1 0 0 0 0 0 6 0 0 1 0 0 0 0 21 384 41 798 Other specified carcinomas 142 0 0 0 0 0 1 0 4 1 0 0 0 0 0 0 1 2 1 4 Carcinoma, unspecified 171 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 3 4 0 6 Malignant thymoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 658 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrosarcoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 26 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 88 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 1 36 11 1 Malignant fibroepithelial tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 45 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 55 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 145 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Nadaljevanje —> Continued —> Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C19 C20 C21 C22 C23 C24 C25 C26 C30 C31 C32 C33 C34 C37 C38 C39 C40 C41 C43 Vse vrste / All types 13961 96 384 27 126 36 80 287 6 13 14 119 2 1428 14 6 0 11 12 604 Small cell carcinoma 245 0 0 0 0 0 2 1 0 0 0 0 1 223 0 0 0 0 0 0 Non-small cell carcinoma 79 0 0 0 0 0 0 0 0 0 0 0 0 77 0 0 0 0 0 0 Squamous cell carcinoma 1685 0 4 21 0 0 0 0 0 7 10 114 0 351 2 0 0 0 0 0 Basal cell carcinoma 2931 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 374 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 7124 96 368 5 121 31 73 256 4 2 1 1 1 712 0 0 0 0 0 0 Other specified carcinomas 142 0 3 0 0 2 2 6 1 1 1 0 0 37 0 0 0 0 0 0 Carcinoma, unspecified 171 0 8 0 0 2 2 22 0 0 0 3 0 20 0 0 0 0 0 0 Malignant thymoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 12 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 658 0 1 1 0 0 0 0 0 3 2 0 0 0 0 0 0 0 0 604 Fibrosarcoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Fibrohistiocytic sarcoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Leiomyosarcoma 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 Angiosarcoma 8 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 3 0 Chondrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 1 0 Ewing sarcoma/PNET 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 Other specified sarcomas 6 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 26 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 Malignant complex mixed and stromal tumors 88 0 0 0 2 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 Malignant fibroepithelial tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 45 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 55 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Malignant trophoblastic tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 145 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 Malignant tumor, unspecified 15 0 0 0 0 1 1 2 0 0 0 0 0 5 0 0 0 0 0 0 Nadaljevanje —> Continued —> 39 Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C44 C45 C46 C47 C48 C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C60 C61 C62 Vse vrste / All types 13961 3588 45 1 4 15 58 1509 60 10 107 349 5 136 37 0 16 1636 86 Small cell carcinoma 245 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 4 0 Non-small cell carcinoma 79 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1685 612 0 0 0 0 0 0 53 5 81 0 0 0 0 0 14 0 0 Basal cell carcinoma 2931 2928 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 374 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 Adenocarcinoma 7124 26 0 0 0 8 0 1465 0 1 19 280 0 119 36 0 0 1624 0 Other specified carcinomas 142 2 0 0 0 0 0 10 0 0 2 49 0 1 0 0 0 2 0 Carcinoma, unspecified 171 5 0 0 0 0 0 31 0 1 1 0 0 8 0 0 0 1 0 Malignant thymoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 658 0 0 0 0 0 0 0 3 3 0 0 0 0 0 0 2 0 0 Fibrosarcoma 10 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 7 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 0 0 0 0 3 16 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 14 2 0 0 0 1 3 0 1 0 0 0 1 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 8 1 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 10 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 8 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 4 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 3 0 0 0 1 0 0 0 0 0 0 0 0 Sarcoma, unspecified 26 4 0 0 0 0 17 0 0 0 0 0 1 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 88 0 0 0 0 0 0 0 0 0 2 19 2 5 1 0 0 0 0 Malignant fibroepithelial tumors 2 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 45 0 45 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 3 Dysgerminoma and seminoma 55 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 54 Other malignant germ cell tumors 28 0 0 0 0 1 1 0 0 0 0 0 0 2 0 0 0 0 23 Malignant trophoblastic tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 Malignant gliomas 145 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 15 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Nadaljevanje —> Continued —> Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C63 C64 C65 C66 C67 C68 C69 C70 C71 C72 C73 C74 C75 C76 C77 C78 C79 C80 Vse vrste / All types 13961 4 361 43 14 330 3 33 5 144 3 194 14 2 9 30 36 16 74 Small cell carcinoma 245 0 0 0 0 2 0 0 0 0 0 0 0 0 0 3 1 1 3 Non-small cell carcinoma 79 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 Squamous cell carcinoma 1685 0 0 2 0 3 0 4 0 0 0 1 0 0 0 15 0 2 4 Basal cell carcinoma 2931 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 374 0 0 40 13 312 3 0 0 0 0 0 0 0 0 0 0 1 0 Adenocarcinoma 7124 0 350 0 0 2 0 0 0 0 0 189 3 1 6 4 20 8 40 Other specified carcinomas 142 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 1 1 3 Carcinoma, unspecified 171 0 7 1 1 9 0 0 0 0 0 0 0 0 0 4 13 2 14 Malignant thymoma 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 10 0 0 0 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0 Malignant melanoma 658 0 0 0 0 0 0 29 1 0 0 0 0 0 0 2 0 1 6 Fibrosarcoma 10 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 24 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 14 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 8 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 Kaposi sarcoma 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 26 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 88 0 3 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Malignant fibroepithelial tumors 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 45 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 55 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 145 0 0 0 0 0 0 0 0 142 3 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 6 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 6 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 Malignant tumor, unspecified 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 Tabela 4b: Incidenca malignih neoplazem limfaticnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2018. Table 4b: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2018. Šifra ICD-O-3 ICD-O-3 code Histološka vrsta Histology type Število Number Vse vrste All types Moški in ženske / Males and females 787 Moški / Males 437 Ženske / Females 350 9727, 9728, 9835, 9836, 9811-9818 Neoplazme nezrelih celic B 12Precursor lymphoid neoplasms B 9727, 9835, 9811 Limfoblastni limfom B / levkemija B, BDO 10B lymphoblastic lymphoma / leukaemia, NOS 9812, 9814 Limfoblastni limfom B / levkemija B z rekurentnimi citogenetskimi anomalijami 2B lymphoblastic lymphoma / leukaemia with recurrent genetic abnormalities 9729, 9837 Neoplazme nezrelih celic T 7Precursor lymphoid neoplasms T 9837 Limfoblastni limfom T / levkemija T 7T Lymphoblastic lymphoma / leukaemia 9591-9597, 96709699, 9712, 97319738, 9760-9764,9823, 9826,9833, 9940 Periferni B-celicni limfom / neoplazme zrelih celic B 667Mature B-cell neoplasms 9670, 9823 Kronicna limfaticna levkemija B / drobnocelicni limfocitni limfom 152Chronic lymphocytic leukaemia / small lymphocytic lymphoma 9689 Splenicni limfom robne cone 10Splenic marginal zone lymphoma 9591 Ne-Hodgkinovi limfomi, BDO; primarni vranicni limfom / levkemija, nerazvršceni; difuzni drobnocelicni limfom B rdece pulpe; posebna oblika dlakastocelicne levkemije 13Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant 9940 Dlakastocelicna levkemija 4Hairy cell leukaemia 9671 Limfoplazmacitni limfom 4Lymphoplasmacytic lymphoma 9761 Waldenströmova makroglobulinemija 6Waldenström macroglobulinemia 9762 Bolezen težkih verig, BDO 1Heavy chain disease, NOS 9732, 9733 Multipli mielom 135Plasma cell myeloma 9731, 9734 Solitarni kostni in zunajkostni plazmacitom 7Solitary plasmacytoma of bone and extraosseous 9699, nodalni B-celicni limfom robne cone, nodalni 37Marginal zone B-cell lymphoma, nodal 9699, ekstranodalni B-celicni limfom robne cone, ekstranodalni 26Marginal zone B-cell lymphoma, extranodal 9690 Folikularni limfom, BDO 4Follicular lymphoma, NOS 9691, 9695 Folikularni limfom, gradus 1 in 2 44Follicular lymphoma, grade 1 and 2 9698 Folikularni limfom, gradus 3 17Follicular lymphoma, grade 3 9597 Primarni kožni limfom folikularnih centrov 1Primary cutaneous follicle centre lymphoma 9673 Limfom plašcnih celic 26Mantle cell lymphoma 9680, 9684 Difuzni velikocelicni limfom B (DLBCL), BDO; primarni DLBCL CŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCLpovezan s kronicnim vnetjem; nerazvršceni B-celicni limfom, mejni primer med difuznim velikocelicnim limfomom B in Burkittovim limfomom 171Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma Šifra ICD-O-3 ICD-O-3 code Histološka vrsta Histology type 9687 Burkittov limfom / levkemija Burkitt lymphoma / leukaemia 9679 Primarni mediastinalni (timicni) velikocelicni limfom B Primary mediastinal (thymic) large B-cell lymphoma Neoplazme zrelih celic T/NKMature T- and NK-cell neoplasms 9827, 9831, 9834, 9948 Levkemicne neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms 9831 Levkemija velikih granuliranih limfocitov T T-cell large granular lymphocytic leukemia 9948 Agresivna NK celicna levkemija Aggressive NK cell leukaemia 9827 Limfom T odraslih / levkemija T odraslih Adult T-cell lymphoma / leukaemia 9700, 9701, 9708, 9709, 9716-9719 Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms 9717 Limfom T z enteropatijo Enteropathy-associated T-cell lymphoma 9700 Fungoidna mikoza Mycosis fungoides 9701 Sézaryjev sindrom Sézary syndrome 9718 Primarne kožne CD30+ T-celicne limfoproliferativne bolezni Primary cutaneous CD30+ T-cell lymphoproliferative disorder 9709 Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types 9702, 9705, 9714 Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms 9702 Periferni limfom T (BDO- in ALK-negativen ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL) 9705 Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma 9714 Anaplasticni velikocelicni limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive 9650-9667 Hodgkinov limfom (HL) Hodgkin lymphoma (HL) 9659 HL z nodularno limfocitno predominanco Nodular lymphocyte predominant HL 9650 Klasicni HL Classical HL 9663, 9664, 9667 Klasicni HL, tip nodularne skleroze Nodular sclerosis classical HL 9651 Z limfociti bogat klasicni HL Lymphocyte-rich classical HL 9652 Mešanocelicni tip klasicnega HL Mixed cellularity classical HL 9590, 9832 Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukemia 9590 Maligni limfom, BDOMalignant lymphoma, NOS 9750-9759 Neoplazme histiocitov in dendriticnih celicHistiocytic and dendritic cell neoplasms 9751 Histiocitoza Langerhansovih celic, NOS Langerhans cell histiocytosis, NOS 9755 Histiocitni sarkom Histiocytic sarcoma Število Number 6 3 43 4 1 1 2 12 3 6 1 1 1 27 14 12 1 51 4 2 28 4 13 3 3 4 3 1 Tabela 4c: Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2018. Table 4c: Incidence of non-Hodgkin’s lymphomas (NHL) by cancer site, Slovenia 2018. Šifra MKB-8 Primarna lokacija Vse starosti ICD-8 code Primary site All ages Vsi NHL All NHL 424 143 Dlesni Gum 1 144 Ustno dno Floor of mouth 1 146 Orofarinks Oropharynx 1 147 Epifarinks Epipharynx 2 148 Hipofarinks Hypopharynx 1 151 Želodec Stomach 25 152 Tanko crevo Small intestine 9 153 Debelo crevo Colon 1 157 Trebušna slinavka Pancreas 1 160 Nos, obnosne votline, drugo Nose, paranasal sinuses, other 4 162 Sapnik, sapnica, pljuca Trachea, bronchus, lung 6 170 Kosti Bone 3 173 Koža, drugi malignomi Skin, other malignancies 12 174 Dojka Breast 4 186 Modo Testis 1 189 Ledvica, secevod, drugo Kidney, ureter, etc. 1 190 Oko Eye 13 191 Možgani Brain 11 193 Šcitnica Thyroid gland 1 202 Bezgavke Lymph nodes 326 BDO - brez drugih oznak / NOS - not otherwise specified EBV - Epstein-Barr virusCŽS - centralni živcni sistem / CNS - central nervous systemNK - natural killer cells ALCL - anaplasticni velikocelicni limfom / anaplastic large cell lymphoma Tabela 5: Incidenca raka po stadiju, Slovenija 2018. Table 5: Cancer incidence by stage, Slovenia 2018. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage Omejen Localized Razširjen Regional Razsejan Distant Neznan Unknown ** Število Number %* Število Number %* Število Number %* Število Number %* C00-C80 Vse lokacije / All sites Moški in ženske / Males and females Moški / Males Ženske / Females 14754 7893 6861 8340 4324 4016 56,5 54,8 58,5 3650 2012 1638 24,7 25,5 23,9 2526 1402 1124 17,1 17,8 16,4 238 155 83 1,6 2,0 1,2 C00 Ustnica / Lip 35 35 100,0 0 0,0 0 0,0 0 0,0 C01 Baza jezika / Base of tongue 30 9 30,0 20 66,7 1 3,3 0 0,0 C02 Jezik, drugi deli / Tongue, other & unspecified parts 31 10 32,3 21 67,7 0 0,0 0 0,0 C03 Dlesen / Gum 15 5 33,3 10 66,7 0 0,0 0 0,0 C04 Ustno dno / Floor of mouth 30 8 26,7 21 70,0 0 0,0 1 3,3 C05 Nebo / Palate 17 10 58,8 7 41,2 0 0,0 0 0,0 C06 Usta, drugi deli / Mouth, other & unspecified parts 16 5 31,3 11 68,8 0 0,0 0 0,0 C07 Parotidna žleza / Parotid gland 14 7 - 5 - 2 - 0 - C08 Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands 1 0 - 1 - 0 - 0 - C09 Tonzila / Tonsil 50 4 8,0 45 90,0 1 2,0 0 0,0 C10 Orofarinks / Oropharynx 35 4 11,4 30 85,7 1 2,9 0 0,0 C11 Nazofarinks / Nasopharynx 10 0 - 9 - 1 - 0 - C12 Piriformni sinus / Pyriform sinus 37 7 18,9 29 78,4 1 2,7 0 0,0 C13 Hipofarinks / Hypopharynx 18 1 5,6 14 77,8 3 16,7 0 0,0 C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx 0 0 - 0 - 0 - 0 - C15 Požiralnik / Oesophagus 103 15 14,6 48 46,6 24 23,3 16 15,5 C16 Želodec / Stomach 438 85 19,4 174 39,7 161 36,8 18 4,1 C17 Tanko crevo / Small intestine 57 18 31,6 19 33,3 18 31,6 2 3,5 C18 Debelo crevo / Colon 850 171 20,1 485 57,1 179 21,1 15 1,8 C19 Rektosigmoidna zveza / Rectosigmoid junction 100 19 19,0 49 49,0 28 28,0 4 4,0 C20 Rektum / Rectum 399 86 21,6 226 56,6 77 19,3 10 2,5 C21 Anus in analni kanal / Anus and anal canal 27 7 25,9 17 63,0 2 7,4 1 3,7 C22 Jetra in intrahepaticni vodi / Liver and intrahepatic bile ducts 231 79 34,2 53 22,9 86 37,2 13 5,6 C23 Žolcnik / Gallbladder 60 11 18,3 16 26,7 32 53,3 1 1,7 C24 Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts 130 27 20,8 58 44,6 42 32,3 3 2,3 C25 Trebušna slinavka / Pancreas 428 37 8,6 150 35,0 232 54,2 9 2,1 C26 Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs 8 0 - 1 - 5 - 2 - C30 Nosna votlina in srednje uho / Nasal cavity and middle ear 13 7 - 5 - 1 - 0 - C31 Obnosni sinusi / Accessory sinuses 14 2 - 12 - 0 - 0 - C32 Grlo / Larynx 119 58 48,7 60 50,4 0 0,0 1 0,8 C33 Sapnik / Trachea 2 0 - 1 - 1 - 0 - C34 Sapnica in pljuca / Bronchus and lung 1563 314 20,1 461 29,5 773 49,5 15 1,0 C37 Timus / Thymus 14 10 - 3 - 1 - 0 - C38 Srce, mediastinum, plevra / Heart, mediastinum, pleura Druga in slabo opredeljena mesta v dihalih in prsnih organih 9 2 - 3 - 3 - 1 - C39 Other and ill-defined sites in the respiratory system and intrathoracic organs 0 0 - 0 - 0 - 0 - C40 Kosti, sklepni hrustanec udov / Bone and articular cartilage of limbs 11 3 - 6 - 2 - 0 - C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts 13 5 - 6 - 1 - 1 - C43 Maligni melanom kože / Malignant melanoma of skin 604 442 73,2 138 22,8 23 3,8 1 0,2 C44 Druge maligne neoplazme kože / Skin, excl. melanoma 3603 3569 99,1 29 0,8 2 0,1 3 0,1 C45 Mezoteliom / Mesothelioma 45 14 31,1 25 55,6 5 11,1 1 2,2 C46 Kaposijev sarkom / Kaposi’s sarcoma 1 1 - 0 - 0 - 0 - C47 Periferni živci in avtonomno živcevje Peripheral nerves and autonomic nervous system 4 0 - 2 - 1 - 1 - C48 Peritonej in retroperitonej / Retroperitoneum and peritoneum 16 1 6,3 7 43,8 8 50,0 0 0,0 C49 Drugo vezivno in mehko tkivo / Other connective and soft tissue 58 16 27,6 28 48,3 13 22,4 1 1,7 C50 Dojka / Breast 1526 858 56,2 520 34,1 142 9,3 6 0,4 Nadaljevanje —> Continued —> 44 Tabela 5: Nadaljevanje. Table 5: Continued. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage Omejen Localized Razširjen Regional Razsejan Distant Neznan Unknown ** Število Number %* Število Number %* Število Number %* Število Number %* C51 Žensko zunanje spolovilo / Vulva 62 30 48,4 31 50,0 0 0,0 1 1,6 C52 Nožnica / Vagina 10 5 - 0 - 3 - 2 - C53 Maternicni vrat / Cervix uteri 108 42 38,9 50 46,3 14 13,0 2 1,9 C54 Maternicno telo / Corpus uteri 351 245 69,8 78 22,2 25 7,1 3 0,9 C55 Maternica, neopredeljeno / Uterus, unspecified 5 1 - 3 - 0 - 1 - C56 Jajcnik / Ovary 142 18 12,7 22 15,5 101 71,1 1 0,7 C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs 39 5 12,8 6 15,4 27 69,2 1 2,6 C58 Posteljica / Placenta 0 0 - 0 - 0 - 0 - C60 Penis / Penis 16 11 68,8 5 31,3 0 0,0 0 0,0 C61 Prostata / Prostate 1680 1078 64,2 411 24,5 129 7,7 62 3,7 C62 Modo / Testis 86 62 72,1 15 17,4 9 10,5 0 0,0 C63 Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs 4 3 - 1 - 0 - 0 - C64 Ledvica razen meha / Kidney, excl. renal pelvis 399 246 61,7 83 20,8 66 16,5 4 1,0 C65 Ledvicni meh / Renal pelvis 44 11 25,0 19 43,2 13 29,5 1 2,3 C66 Secevod / Ureter 16 8 50,0 5 31,3 3 18,8 0 0,0 C67 Secni mehur / Bladder 342 248 72,5 49 14,3 39 11,4 6 1,8 C68 Drugi in neopredeljeni secni organi Other and unspecified urinary organs 3 1 - 0 - 2 - 0 - C69 Oko in ocesni adneksi / Eye and adnexa 37 34 91,9 3 8,1 0 0,0 0 0,0 C70 Meninge / Meninges 5 5 - 0 - 0 - 0 - C71 Možgani / Brain Hrbtni mozeg, možganski živci in drugi deli 160 160 100,0 0 0,0 0 0,0 0 0,0 C72 centralnega živcnega sistema (CŽS) Spinal cord, cranial nerves and other parts of central nervous system (CNS) 3 3 - 0 - 0 - 0 - C73 Šcitnica / Thyroid gland 194 148 76,3 36 18,6 10 5,2 0 0,0 C74 Nadledvicna žleza / Adrenal gland 15 13 86,7 0 0,0 2 13,3 0 0,0 C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures 2 1 - 1 - 0 - 0 - C76 Druga in slabo opredeljena mesta / Other and ill-defined sites 13 0 - 7 - 5 - 1 - C77 Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes 30 0 0,0 0 0,0 3 10,0 27 90,0 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs 65 0 0,0 0 0,0 65 100,0 0 0,0 C79 Metastaze, drugje / Metastases of other sites 26 0 0,0 0 0,0 26 100,0 0 0,0 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site 112 0 0,0 0 0,0 112 100,0 0 0,0 Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage I II III + IV Neznan / Unknown Število Number %* Število Number %* Število Number %* Število Number %* C81 Hodgkinov limfom / Hodgkin’s lymphoma 51 5 9,8 22 43,1 21 41,2 3 5,9 C82 Folikularni ne-Hodgkinov limfom / Follicular non-Hodgkin’s lymphoma 129 38 29,5 14 10,9 71 55,0 6 4,7 C83 Difuzni ne-Hodgkinov limfom / Diffuse non-Hodgkin’s lymphoma 239 40 16,7 23 9,6 153 64,0 23 9,6 C84 Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas 40 5 12,5 2 5,0 24 60,0 9 22,5 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin’s lymphoma 16 1 6,3 1 6,3 8 50,0 6 37,5 * Odstotki niso racunani, ce je število novih primerov manjše od 15 Percentages are not calculated when number of new cases is less than 15 ** Vkljuceni tudi primeri, ki so registrirani samo iz zdravniških porocil o vzroku smrti, razen pri C78-C80, kjer so prišteti k razsejanemu stadiju Cases registered from death certificates only are included, except for C78-C80, where they are added to the distant stage Prevalenca Prevalence Tabela 6: Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2018. Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2018. Šifra MKB ICD code Primarna lokacija* Primary site* Spol Sex Leta po diagnozi Years after diagnosis Celotna prevalenca Lifetime prevalence <1 1-4 5-9 10+ Vsi / All C00-C96 Vse lokacije All sites M+Ž M Ž 13054 6857 6197 36396 18721 17675 31455 15847 15608 43944 16671 27273 116507 53522 62985 C00-C14 Usta in žrelo Mouth and pharynx M Ž 228 63 541 231 436 158 513 287 1718 739 C15 Požiralnik Oesophagus M Ž 51 7 39 14 22 6 21 12 133 39 C16 Želodec Stomach M Ž 174 113 342 213 283 193 411 358 1210 877 C18 Debelo crevo Colon M Ž 376 297 1142 871 1175 900 1079 1154 3772 3222 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 284 146 879 479 933 528 940 823 3036 1976 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 82 24 124 42 31 6 23 12 260 84 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 51 43 65 74 33 40 35 39 184 196 C25 Trebušna slinavka Pancreas M Ž 108 95 95 90 30 34 25 34 258 253 C32 Grlo Larynx M Ž 98 13 221 28 219 34 346 58 884 133 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung M Ž 609 391 833 650 373 270 405 215 2220 1526 C43 Maligni melanom kože Malignant melanoma of skin M Ž 307 284 1001 924 863 963 1011 1683 3182 3854 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 1707 1829 5092 5145 4109 4374 4414 5488 15322 16836 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 35 29 69 106 68 73 205 216 377 424 C50 Dojka Breast M Ž 11 1444 35 4715 39 4411 33 8002 118 18572 C53 Maternicni vrat Cervix uteri M Ž - 94 - 317 - 415 - 2637 - 3463 C54 Maternicno telo Corpus uteri M Ž - 327 - 1109 - 1035 - 2376 - 4847 C56 JajcnikOvary M Ž - 112 - 296 - 260 - 910 - 1578 C61 Prostata Prostate M Ž 1590 - 5497 - 5019 - 3011 - 15117 - C62 Modo Testis M Ž 85 - 474 - 476 - 1554 - 2589 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 245 100 646 338 602 302 718 511 2211 1251 C67 Secni mehur Bladder M Ž 216 61 564 184 389 120 444 153 1613 518 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 73 43 111 79 69 57 210 163 463 342 C73 Šcitnica Thyroid gland M Ž 53 134 153 589 157 502 264 1150 627 2375 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 21 26 94 95 92 101 362 342 569 564 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma M Ž 189 162 540 502 449 436 565 610 1743 1710 C90 Difuzni plazmocitom in maligne neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 68 54 171 127 81 95 59 54 379 330 C91-C95 Levkemije Leukaemias M Ž 155 111 416 301 304 236 430 380 1305 1028 * Pri posameznih lokacijah je pri prikazu prevalence oseba z vec raki vkljucena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z vec raki šteje le enkrat Person diagnosed with more than one cancer is included as a prevalent case in each cancer site, but for all sites together (C00-C96) each person is counted once only Umrljivost Mortality Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2018. Vir: Nacionalni inštitut za javno zdravje Table 7: Cancer mortality by age and by sex, Slovenia 2018. Source: National Institute of Public Health Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Vse starosti All ages Starost / Age 0-19 20-49 50-74 75+ C00-C97 Vse lokacije All sites M+Ž M Ž 6548 3593 2955 13 7 6 180 88 92 2978 1779 1199 3377 1719 1658 C00-C14 Usta in žrelo Mouth and pharynx M Ž 128 33 0 0 7 2 90 22 31 9 C15 Požiralnik Oesophagus M Ž 71 21 0 0 6 0 44 5 21 16 C16 Želodec Stomach M Ž 198 136 0 0 4 5 91 43 103 88 C18 Debelo crevo Colon M Ž 264 196 0 0 1 7 113 57 150 132 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 179 109 0 0 5 1 82 32 92 76 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 180 96 0 0 5 0 108 41 67 55 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 54 59 0 0 0 1 29 21 25 37 C25 Trebušna slinavka Pancreas M Ž 211 189 0 0 3 2 125 74 83 113 C32 Grlo Larynx M Ž 33 7 0 0 1 0 19 3 13 4 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung M Ž 750 454 0 0 9 5 482 295 259 154 C43 Maligni melanom kože Malignant melanoma of skin M Ž 81 50 1 0 5 4 44 15 31 31 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž 27 26 0 0 0 0 4 1 23 25 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 23 25 1 0 4 0 10 11 8 14 C50 Dojka Breast M Ž 5 473 0 0 0 33 1 171 4 269 C53 Maternicni vrat Cervix uteri M Ž - 42 - 0 - 3 - 18 - 21 C54 Maternicno telo Corpus uteri M Ž - 91 - 0 - 1 - 43 - 47 C56 Jajcnik Ovary M Ž - 150 - 0 - 9 - 73 - 68 C61 Prostata Prostate M Ž 450 - 0 - 1 - 113 - 336 - C62 Modo Testis M Ž 9 - 0 - 6 - 3 - 0 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 115 73 0 0 4 0 53 25 58 48 C67 Secni mehur Bladder M Ž 157 79 0 0 1 3 51 21 105 55 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 111 79 3 5 16 7 65 36 27 31 C73 Šcitnica Thyroid gland M Ž 5 13 0 0 0 0 4 3 1 10 C81 Hodgkinov limfom Hodgkin’s lymphoma M Ž 7 4 0 0 1 0 4 1 2 3 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma M Ž 93 94 0 0 3 1 43 32 47 61 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 53 55 0 0 0 0 26 19 27 36 C91-C95 Levkemije Leukaemias M Ž 103 103 1 0 2 1 43 28 57 74 Preživetje Survival Tabela 8: Eno- in pet-letno cisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2014–2018. Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2014–2018 by sex. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Eno-letno preživetje s 95 % intervalom zaupanja Pet-letno preživetje s 95 % intervalom zaupanja One-year survival with 95% confidence interval Five-year survival with 95% confidence interval C00-C96 brez C44** Vse lokacije All sites M+Ž M Ž 74,6 74,3-75,0 73,2 72,7-73,7 76,3 75,8-76,9 58,9 58,4-59,5 57,3 56,5-58,0 61,0 60,3-61,8 C00-C14 Usta in žrelo Mouth and pharynx M Ž 73,0 70,6-75,5 85,3 81,6-89,1 45,4 42,3-48,7 65,0 59,1-71,5 C15 Požiralnik Oesophagus M Ž 39,7 34,9-45,2 38,8 29,6-50,9 10,3 7,1-14,8 15,2 9,0-25,5 C16 Želodec Stomach M Ž 52,7 50,0-55,6 49,6 46,2-53,2 29,9 26,9-33,2 32,0 28,3-36,1 C18 Debelo crevo Colon M Ž 78,8 77,0-80,7 77,4 75,3-79,5 61,4 58,6-64,3 62,9 59,8-66,1 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 84,8 82,9-86,7 80,5 77,8-83,3 64,3 61,1-67,7 59,9 55,9-64,1 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 35,1 31,9-38,7 31,4 26,5-37,2 10,0 7,7-13,0 12,9 9,2-18,0 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 35,9 31,6-40,8 32,2 28,3-36,7 13,8 10,6-18,0 14,8 11,4-19,2 C25 Trebušna slinavka Pancreas M Ž 26,7 24,1-29,6 26,6 23,9-29,6 5,7 4,2-7,7 8,1 6,4-10,3 C32 Grlo Larynx M Ž 86,9 83,6-90,4 * 64,0 58,3-70,2 * C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung M Ž 43,6 42,2-45,1 52,2 50,3-54,2 17,9 16,6-19,3 26,2 24,3-28,3 C43 Maligni melanom kože Malignant melanoma of skin M Ž 97,6 96,4-98,9 98,2 97,1-99,3 90,6 87,6-93,7 91,3 88,2-94,4 C44 Druge maligne neoplazme kože Skin, excl. melanoma M Ž ** ** ** ** C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 76,4 69,8-83,8 81,3 75,9-87,0 55,9 47,0-66,5 57,0 49,6-65,6 C50 Dojka Breast M Ž * 96,6 96,0-97,1 * 87,3 86,0-88,7 C53 Maternicni vrat Cervix uteri M Ž - - 84,4 81,2-87,6 - - 69,6 65,2-74,3 C54 Maternicno telo Corpus uteri M Ž - - 91,5 90,0-92,9 - - 80,2 77,5-83,0 C56 JajcnikOvary M Ž - - 74,5 71,3-77,8 - - 41,4 37,4-45,8 C61 Prostata Prostate M Ž 97,5 97,0-98,1 - - 94,1 92,8-95,4 - - C62 Modo Testis M Ž 99,1 98,2-99,9 - - 96,8 95,0-98,7 - - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 80,1 77,8-82,5 76,4 73,0-79,9 67,2 63,6-71,0 64,6 59,7-70,0 C67 Secni mehur Bladder M Ž 75,6 73,0-78,2 66,1 61,7-70,8 56,0 51,9-60,4 47,5 41,9-53,7 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 48,7 44,6-53,2 45,9 41,0-51,4 20,1 16,7-24,2 19,1 15,3-23,9 C73 Šcitnica Thyroid gland M Ž 95,0 91,8-98,2 97,3 96,0-98,6 90,0 84,5-96,0 96,8 94,7-99,1 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 90,9 86,1-96,0 91,0 86,1-96,2 79,8 72,3-88,0 84,7 77,3-92,8 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma M Ž 75,7 73,0-78,4 76,2 73,5-79,0 64,2 60,5-68,3 63,6 59,9-67,6 C90 Difuzni plazmocitom in maligne neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 77,9 73,4-82,6 76,4 71,5-81,7 45,5 39,0-53,1 41,7 34,7-50,0 C91-C95 Levkemije Leukaemias M Ž 70,5 67,5-73,7 69,7 66,2-73,4 54,7 50,8-59,0 50,3 45,4-55,8 * Število v analizo vkljucenih bolnikov je v povprecju manjše od 15 na leto / Average number of patients included in the analysis is less than 15 annually** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population Zdravljenje Treatment Tabela 9a: Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2018, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL). Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in2018, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (inparenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given). Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Število kakorkoli zdravljenih* Number of all treated* Število operiranih Number of treated by surgery Število zdravljenih s sistemsko terapijo No. of treated by systemic therapy Število obsevanih Number of treated by radiotherapy Število Number %** Število Number %** Število Number %** Število (od tega OIL) Number (IOL only) %** C00-C96 Vse lokacije / All sites 15864 12905 81,3 10110 63,7 4465 28,1 3376 (2957) 21,3 C00-C14 Usta in žrelo Mouth and pharynx 338 316 93,5 199 58,9 23 6,8 218 (217) 64,5 C15 Požiralnik Oesophagus 102 62 60,8 17 16,7 34 33,3 46 (45) 45,1 C16 Želodec Stomach 436 274 62,8 209 47,9 149 34,2 59 (56) 13,5 C18 Debelo crevo Colon 842 721 85,6 703 83,5 199 23,6 11 (11) - C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 497 431 86,7 360 72,4 194 39,0 195 (186) 39,2 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 229 89 38,9 32 14,0 47 20,5 8 (6) - C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 189 85 45,0 70 37,0 24 12,7 3 (3) - C25 Trebušna slinavka Pancreas 427 197 46,1 96 22,5 142 33,3 19 (15) 4,4 C32 Grlo Larynx 119 114 95,8 70 58,8 1 - 90 (90) 75,6 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung 1560 1105 70,8 373 23,9 545 34,9 560 (494) 35,9 C43 Maligni melanom kože Malignant melanoma of skin 604 601 99,5 595 98,5 37 6,1 27 (27) 4,5 C44 Druge maligne neoplazme kože Skin, excl. melanoma 3603 3538 98,2 3415 94,8 22 0,6 102 (101) 2,8 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 74 69 93,2 52 70,3 24 32,4 43 (42) 58,1 C50 Dojka Breast 1520 1465 96,4 1248 82,1 1366 89,9 1021 (735) 67,2 C53 Maternicni vrat Cervix uteri 108 90 83,3 58 53,7 6 - 52 (52) 48,1 C54 Maternicno telo Corpus uteri 351 332 94,6 314 89,5 62 17,7 133 (130) 37,9 C56 JajcnikOvary 141 111 78,7 105 74,5 92 65,2 0 (0) - C61 Prostata Prostate 1678 1144 68,2 795 47,4 411 24,5 200 (189) 11,9 C62 Modo Testis 86 86 100 85 98,8 46 53,5 1 (1) - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 442 343 77,6 317 71,7 33 7,5 15 (13) 3,4 C67 Secni mehur Bladder 342 306 89,5 301 88,0 56 16,4 20 (15) 5,8 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 168 149 88,7 147 87,5 76 45,2 105 (102) 62,5 C73 Šcitnica Thyroid gland 194 186 95,9 180 92,8 174 89,7 105 (105) 54,1 C81 Hodgkinov limfomHodgkin’s lymphoma 51 46 90,2 3 - 45 88,2 22 (22) 43,1 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne 424 319 75,2 40 9,4 243 57,3 135 (135) 31,8 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms 142 117 82,4 4 - 114 80,3 23 (21) 16,2 C91-C95 Levkemije Leukaemias 351 137 39,0 1 - 137 39,0 12 (12) - * Število bolnikov zdravljenih s specificnim onkološkim zdravljenjem v okviru prvega zdravljenja ne glede na nacin zdravljenja (vkljucno z drugimi zdravljenji, ki ne spadajo med operacijo, sistemsko terapijoali obsevanje) Number of all treated patients with specific oncological treatment regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy) ** Odstotki niso racunani, ce je število zdravljenih manjše od 15 Percentages are not calculated for less than 15 cases Tabela 9b: Število bolnikov (brez primerov, registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2018, ki so bili v okviru prvega zdravljenja operirani*, po ustanovi posega. Table 9b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2018, that were treated by surgery during their first treatment* by treatment institution. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new casesŠtevilo operiranih Number of treated by surgerySplošna bolnišnica CeljeSplošna bolnišnica JeseniceSplošna bolnišnica IzolaUniverzitetni klinicni centerLjubljanaOnkološki inštitut LjubljanaUniverzitetni klinicni centerMariborSplošna bolnišnica Murska SobotaSplošna bolnišnica NovaGoricaSplošna bolnišnica NovomestoSplošna bolnišnicaPtujSplošna bolnišnica SlovenjGradecZasebne ordinacijePrivate clinicsOstale ustanove** Other institutions** C00-C96 Vse lokacije All sites 15864 10110 948 317 267 2576 1432 1681 369 285 484 125 538 942 146 C00-C14 Usta in žrelo Mouth and pharynx 338 199 2 3 1 128 2 56 2 2 2 0 0 1 0 C15 Požiralnik Oesophagus 102 17 0 0 0 12 0 3 0 0 0 0 0 2 0 C16 Želodec Stomach 436 209 13 8 6 93 7 61 5 2 2 0 3 6 3 C18 Debelo crevo Colon 842 703 52 64 40 194 39 107 39 32 39 17 28 33 19 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 497 360 13 18 31 87 79 42 14 4 8 11 15 27 11 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 229 32 0 0 1 20 2 9 0 0 0 0 0 0 0 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 189 70 1 2 7 37 0 19 0 0 1 1 0 2 0 C25 Trebušna slinavka Pancreas 427 96 0 0 7 54 0 35 0 0 0 0 0 0 0 C32 Grlo Larynx 119 70 2 0 0 58 0 9 0 1 0 0 0 0 0 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung 1560 373 0 1 0 116 1 84 0 0 0 0 1 167 3 C43 Maligni melanom kože Malignant melanoma of skin 604 595 63 40 30 123 42 90 23 23 28 5 23 85 20 C44 Druge maligne neoplazme kože Skin, excl. melanoma 3603 3415 541 158 56 626 34 593 199 101 267 84 127 592 37 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 74 52 2 0 0 10 31 1 4 1 0 1 0 1 1 C50 Dojka Breast 1520 1248 25 0 14 2 941 186 0 49 1 0 27 0 3 C53 Maternicni vrat Cervix uteri 108 58 2 0 0 28 3 5 2 0 6 1 2 0 9 C54 Maternicno telo Corpus uteri 351 314 23 7 3 147 42 43 13 6 8 2 10 0 10 C56 JajcnikOvary 141 105 7 2 0 56 14 16 1 1 1 0 3 0 4 C61 Prostata Prostate 1678 795 147 10 24 184 1 87 30 32 46 0 218 9 7 C62 Modo Testis 86 85 13 0 10 38 0 13 1 3 5 0 2 0 0 C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 442 317 12 0 11 136 0 52 21 15 23 0 44 1 2 C67 Secni mehur Bladder 342 301 16 0 19 112 0 62 9 11 40 0 30 1 1 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 168 147 0 0 0 107 0 38 0 0 0 0 0 0 2 C73 Šcitnica Thyroid gland 194 180 6 0 0 18 135 10 0 0 0 0 0 6 5 C81 Hodgkinov limfomHodgkin’s lymphoma 51 3 0 0 0 2 1 0 0 0 0 0 0 0 0 C82-C85 ne-Hodgkinovi limfominon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne 424 40 1 0 2 17 8 6 0 0 2 0 0 2 2 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms 142 4 0 0 0 2 0 2 0 0 0 0 0 0 0 C91-C95 Levkemije Leukaemias 351 1 0 0 0 0 0 1 0 0 0 0 0 0 0 * Bolniki, ki so bili v okviru prvega zdravljenja operirani vec kot enkrat, so vkljuceni le s prvo operacijo Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only ** V posamezni ustanovi so operirali manj kot 30 bolnikov Less then 30 patients were treated by surgery in individual institution Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti) v Sloveniji, zbolelih leta 2018, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po ustanovi zdravljenja. Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2018, that were treated by systemic therapy during their first treatment* by treatment institution. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new casesŠtevilo zdravljenih s sistemsko terapijo Number of treatedsystemic therapySplošna bolnišnica CeljeUniverzitetna klinika GolnikSplošna bolnišnica IzolaUniverzitetni klinicni centerLjubljanaOnkološki inštitut LjubljanaUniverzitetni klinicni centerMariborSplošna bolnišnica Murska SobotaSplošna bolnišnica Nova GoricaSplošna bolnišnica Novo mestoSplošna bolnišnica SlovenjGradecZasebne ordinacijePrivate clinicsOstale ustanove** Other institutions** C00-C96 Vse lokacije All sites 15864 4465 103 161 38 393 2673 839 20 79 30 82 24 23 C00-C14 Usta in žrelo Mouth and pharynx 338 23 0 0 0 1 22 0 0 0 0 0 0 0 C15 Požiralnik Oesophagus 102 34 0 0 0 0 32 2 0 0 0 0 0 0 C16 Želodec Stomach 436 149 4 0 0 6 98 38 0 1 0 2 0 0 C18 Debelo crevo Colon 842 199 13 0 0 5 120 48 1 1 0 11 0 0 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 497 194 1 0 0 5 165 22 0 0 0 1 0 0 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 229 47 0 0 0 35 2 10 0 0 0 0 0 0 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 189 24 0 0 0 6 9 8 0 1 0 0 0 0 C25 Trebušna slinavka Pancreas 427 142 3 0 0 44 43 44 0 1 0 5 0 2 C32 Grlo Larynx 119 1 0 0 0 0 1 0 0 0 0 0 0 0 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung 1560 545 0 154 0 0 256 134 0 0 0 0 0 1 C43 Maligni melanom kože Malignant melanoma of skin 604 37 0 0 0 0 37 0 0 0 0 0 0 0 C44 Druge maligne neoplazme kože Skin, excl. melanoma 3603 22 4 0 0 2 4 12 0 0 0 0 0 0 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 74 24 0 0 0 3 20 1 0 0 0 0 0 0 C50 Dojka Breast 1520 1366 33 0 10 0 931 319 0 41 0 26 0 6 C53 Maternicni vrat Cervix uteri 108 6 0 0 0 0 5 0 0 0 0 0 0 1 C54 Maternicno telo Corpus uteri 351 62 0 0 0 0 44 17 0 0 0 0 0 1 C56 JajcnikOvary 141 92 0 0 0 0 73 19 0 0 0 0 0 0 C61 Prostata Prostate 1678 411 24 0 25 49 147 63 11 23 16 29 19 5 C62 Modo Testis 86 46 0 0 0 0 46 0 0 0 0 0 0 0 C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 442 33 0 0 0 3 23 6 0 1 0 0 0 0 C67 Secni mehur Bladder 342 56 0 0 0 3 37 12 1 1 0 2 0 0 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 168 76 0 0 0 3 73 0 0 0 0 0 0 0 C73 Šcitnica Thyroid gland 194 174 3 0 0 15 138 9 0 1 0 0 5 3 C81 Hodgkinov limfomHodgkin’s lymphoma 51 45 0 0 0 5 40 0 0 0 0 0 0 0 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne 424 243 3 1 0 17 215 2 0 2 0 1 0 2 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms 142 114 6 0 2 65 0 16 5 4 13 2 0 1 C91-C95 Levkemije Leukaemias 351 137 7 0 0 99 6 19 2 2 1 0 0 1 * Bolniki, ki so v okviru prvega zdravljenja prejeli vec kot eno vrsto sistemskega zdravljenja, so vkljuceni le enkrat Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only ** V posamezni ustanovi so zdravili manj kot 10 bolnikov Less then 10 patients were treated in individual institution Breme najpogostejših rakov Cancer Fact Sheets Vsi raki / All cancer sites (C00–C96) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Število novih primerov v enem letu / Number of new cases per year Moški / Male 8161 Ženske / Female 6939 Skupaj / All 15100 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 38,2 29,1 33,5 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 796,3 667,1 731,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 403,9 306,5 347,7 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 1,85* 2,46* 2,14* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year -0,36 3496 1,4* 2759 0,51* 6255 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 15,5 9,6 12,4 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 341,2 265,3 302,9 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 154,8 92,2 119,0 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 1,07* 1,28* 1,17* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) -1,73* 61021 -0,3 69202 -1,06* 130223 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 5923,0 6655,2 6290,8 1-letna prevalenca / 1-year prevalence 7057 6315 13372 5-letna prevalenca / 5-year prevalence 26782 24601 51383 * Statisticno znacilno / Statistically significant Incidenca Incidence Slovenija1961–2018 Umrljivost Mortality Slovenija1985–2018 Groba in starostno standardizirana stopnja na 100.000 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Crude and age-standardized rate per 100.00 900 800 700 600 500 400 300 200 100 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja MOŠKI Groba stopnja ŽENSKE Starostno standardizirana stopnja MOŠKI Starostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE 900 800 700 600 500 400 300 200 100 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 Leto / Year Prostata / Prostate (C61) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Moški / Male Število novih primerov v enem letu / Number of new cases per year 1651 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 20,2 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 1. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 24,8 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 10,3 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 161,1 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 78,6 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 1,41* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,89 UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 419 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 12,0 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 1,1 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 40,9 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 15,3 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 2,18* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -1,57* PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 15107 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 1466,4 1-letna prevalenca / 1-year prevalence 1588 5-letna prevalenca / 5-year prevalence 7079 * Statisticno znacilno / Statistically significant Incidenca 180 Incidence 160 Slovenija 140 1961–2018 120 100 80 60 40 20 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja MOŠKI Starostno standardizirana stopnja MOŠKI Crude rate MALE Age-standardized rate MALE 180 160 140 120 100 80 Umrljivost 60 1985–2018 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Crude and age-standardized rate per 100.00 MortalitySlovenija 40 20 Pljuca in sapnik / Lung and trachea (C33, C34) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 949 527 1475 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 11,6 7,6 9,8 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 3. 4. 3. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 14,3 9,7 12,2 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 5,7 2,9 4,3 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 92,6 50,6 71,4 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 46,0 22,7 33,3 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 1,46* 5,87* 2,94* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,81 4,77* 1,15* UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 798 412 1210 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 22,8 14,9 19,3 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 4,6 2,0 3,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 77,9 39,6 58,6 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 37,4 16,2 25,8 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 0,03 4,54* 1,5* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,29* 3,39* -0,32 PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 2212 1526 3738 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 214,7 146,8 180,6 1-letna prevalenca / 1-year prevalence 603 391 994 5-letna prevalenca / 5-year prevalence 1434 1041 2475 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2018 120 100 80 60 40 20 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2012 20182000 2003 2006 2009 2015 Groba stopnja MOŠKI Groba stopnja ŽENSKE Starostno standardizirana stopnja MOŠKI Starostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 120 100 80 60 40 20 1985–2018 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 Leto / Year Dojka / Breast (C50) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Ženske / Female Število novih primerov v enem letu / Number of new cases per year 1396 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 20,1 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 2. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 25,8 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 7,8 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 134,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 71,6 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,44* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,63* UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 420 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 15,2 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 1,6 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 40,4 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 14,7 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 0,46 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -1,22 PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 18571 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 1786,0 1-letna prevalenca / 1-year prevalence 1443 5-letna prevalenca / 5-year prevalence 6158 * Statisticno znacilno / Statistically significant Incidenca 160 Incidence 140 Slovenija 1201961–2018 100 80 60 40 20 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja ŽENSKE Starostno standardizirana stopnja ŽENSKE Crude rate FEMALE Age-standardized rate FEMALE 1985–2018 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 UmrljivostMortalitySlovenija Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 120 100 80 60 40 20 160 140 Debelo crevo in danka / Colon and rectum (C18–C20) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 825 565 1390 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 10,1 8,1 9,2 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 4. 3. 5. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 12,4 10,4 11,5 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 4,6 2,5 3,5 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 80,5 54,3 67,3 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 39,3 21,4 29,5 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) -2,74* -2,48* -2,63* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -5,17* -3,96* -4,65* UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 434 317 750 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 12,4 11,5 12,0 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 1,9 0,9 1,4 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 42,3 30,5 36,3 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 18,6 9,1 13,3 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -0,76 -1,05 -0,88* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -3,61* -3,25* -3,36* PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 6802 5193 11995 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 660,2 499,4 579,5 1-letna prevalenca / 1-year prevalence 656 440 1096 5-letna prevalenca / 5-year prevalence 2676 1790 4466 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2018 120 100 80 60 40 20 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2012 20182000 2003 2006 2009 2015 Groba stopnja MOŠKI Groba stopnja ŽENSKE Starostno standardizirana stopnja MOŠKI Starostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 120 100 80 60 40 20 1985–2018 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 Leto / Year Koža, razen melanoma / Skin, non-melanoma (C44) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 1512 1524 3036 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 18,5 22,0 20,1 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 2. 1. 1. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 22,7 28,2 25,2 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 7,4 6,1 6,7 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 147,5 146,5 147 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 69,6 57,7 62,2 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 5,63* 5,65* 5,64* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 2,99* 4,55* 3,82* UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 17 21 38 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 0,5 0,8 0,6 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,03 0,01 0,02 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 1,6 2,0 1,8 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 0,6 0,4 0,5 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 3,82 3,69 3,88 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,18 -0,52 -1,22 PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 15306 16829 32135 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 1485,7 1618,5 1552,4 1-letna prevalenca / 1-year prevalence 1702 1829 3531 5-letna prevalenca / 5-year prevalence 6787 6970 13757 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2018 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2012 20182000 2003 2006 2009 2015 120 100 80 60 40 20 0 200 160 140 180 * Statisticno znacilno / Statistically significant Leto / Year Groba stopnja MOŠKI Groba stopnja ŽENSKE Starostno standardizirana stopnja MOŠKI Starostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE Umrljivost Mortality Slovenija Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 200 180 160 140 120 100 80 60 40 20 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 Leto / Year 1985–2018 0 Kožni melanom / Malignant melanoma of skin (C43) INCIDENCA (povprecje v obdobju 2014-2018) / INCIDENCE (average during 2014–2018) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 302 266 569 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 3,7 3,8 3,8 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 6. 6. 6. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 4,5 4,9 4,7 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 1,8 1,5 1,6 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 29,5 25,6 27,5 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 16,4 14,6 15,2 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 3,67* 1,42* 2,57* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,3 0,42 0,82* UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 70 52 122 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,0 1,9 2,0 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,4 0,2 0,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 6,9 5,0 5,9 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 3,4 2,0 2,6 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 1,31 -1,48 -0,04 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -1,55 -4,58* -2,89* PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 3182 3854 7036 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 308,9 370,6 339,9 1-letna prevalenca / 1-year prevalence 307 284 591 5-letna prevalenca / 5-year prevalence 1308 1208 2516 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2018 35 25 20 15 10 5 0 30 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2012 20182000 2003 2006 2009 2015 Groba stopnja MOŠKI Groba stopnja ŽENSKE Starostno standardizirana stopnja MOŠKI Starostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE MortalitySlovenija1985–2018 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 5 35 30 25 20 15 Umrljivost 10 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 Leto / Year Glava in vrat / Head and neck (C00–C14, C30–C32) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 377 101 478 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 4,6 1,4 3,2 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 5. 15. 7. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 5,7 1,9 4,0 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 2,5 0,6 1,5 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 36,8 9,7 23,1 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 20,2 4,9 12,3 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) -0,43 1,01 -0,09 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,19* -0,53 -1,74* UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014-2018) Število smrti v enem letu / Number of deaths per year 176 36 212 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 5,0 1,3 3,4 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 1,1 0,2 0,6 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 17,2 3,5 10,3 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 8,9 1,5 5,0 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -1,67* 0,82 -1,19 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -3,82* 0,25 -3,02* PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 2684 939 3623 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 260,5 90,3 175,0 1-letna prevalenca / 1-year prevalence 336 90 426 5-letna prevalenca / 5-year prevalence 1119 362 1481 * Statisticno znacilno / Statistically significant 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2018 30 25 20 15 10 5 45 40 35 Groba stopnja MOŠKI Groba stopnja ŽENSKE Starostno standardizirana stopnja MOŠKI Starostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija1985–2018 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 30 25 20 15 10 5 45 40 35 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Maternicno telo / Corpus uteri (C54) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Ženske / Female Število novih primerov v enem letu / Number of new cases per year 356 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 5,1 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 5. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 6,6 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 2,0 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 34,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 16,1 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,06* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,08 UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 67 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,4 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 6,4 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 2,2 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 6,08* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 5,96* PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 4845 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 465,9 1-letna prevalenca / 1-year prevalence 325 5-letna prevalenca / 5-year prevalence 1434 * Statisticno znacilno / Statistically significant Incidenca 40 Incidence 35 Slovenija 30 1961–2018 25 20 15 10 5 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba stopnja ŽENSKE Starostno standardizirana stopnja ŽENSKE Crude rate FEMALE Age-standardized rate FEMALE 40 35 30 25 20 Umrljivost 15 Mortality10 Slovenija 5 1985–2018 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Crude and age-standardized rate per 100.00 Ne-Hodgkinov limfom / Non-Hodgkin’s lymphoma (C82–C85) INCIDENCA (povprecje v obdobju 2014–2018) / INCIDENCE (average during 2014–2018) Moški / Male Ženske / Female Skupaj / All Število novih primerov v enem letu / Number of new cases per year 224 204 427 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 2,7 2,9 2,8 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 10. 7. 9. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%) 3,4 3,8 3,5 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 1,3 1,0 1,1 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 21,8 19,6 20,7 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 11,8 8,7 10,1 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 4,35* 4,06* 4,26* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 2,33 3,39* 2,86* UMRLJIVOST (povprecje v obdobju 2014–2018) / MORTALITY (average during 2014–2018) Število smrti v enem letu / Number of deaths per year 88 90 178 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,5 3,3 2,8 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,4 0,2 0,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 8,5 8,7 8,6 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 3,8 2,5 3,1 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 6,27* 4,58* 5,39* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 2,87 2,44 2,73 PREVALENCA (na dan 31.12.2018) / PREVALENCE (on December 31, 2018) Število živih oseb z diagnozo raka ob koncu leta 2018 (prevalenca) / Persons living with cancer at the end of 2018 (prevalence) 1740 1706 3446 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2018 168,9 164,1 166,5 1-letna prevalenca / 1-year prevalence 188 161 349 5-letna prevalenca / 5-year prevalence 726 662 1388 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2018 30 25 20 15 10 5 0 1961 1964 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2012 20182000 2003 2006 2009 2015 Groba stopnja MOŠKI Groba stopnja ŽENSKE Starostno standardizirana stopnja MOŠKI Starostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija1985–2018 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 30 25 20 15 10 5 0 1985 1988 1991 1994 1997 2000 2003 2006 2009 2012 2015 Leto / Year Pojmovnik62Incidenca Umrljivost Prevalenca PreživetjeGroba stopnja Starostno standardizirana stopnja Kumulativna stopnja Kumulativno tveganje Ocena incidence PojmovnikDefinicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA: http://www.slora.si/definicije-kazalnikov-in-metod. Število vseh na novo ugotovljenih primerov raka v tocno doloceni populaciji v enem koledarskem letu. Število vseh umrlih za doloceno boleznijo v tocno doloceni populaciji v enem koledarskem letu. Število vseh bolnikov z doloceno boleznijo, ki so bili živi na izbrani datum (po- navadi zadnji dan v letu). Glede na cas, kdaj so zboleli, locimo: .Celotna prevalenca upošteva vse bolnike z rakom ne glede na to, kdaj so zboleli. .Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v tocno dolocenem obdobju pred datumom izracuna. Na primer, v enoletno delno prevalenco so vkljuceni bolniki, ki so zboleli leto dni pred datumom izracuna ter so na ta datum še živi. Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V porocilu podajamo cisto preživetje, izracunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proucevanega raka (hipoteticen primer, v katerem ne umirajo zaradi drugih vzrokov smrti). Incidenca ali umrljivost, preracunani na velikost opazovane populacije. Obicajno je izražena na 100.000 prebivalcev. Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, ce bi bila starostna struktura te populacije enaka kot je v standar- dni populaciji. Uporabljene so tri standardne populacije: svetovna (Segi 1961), evropska (Doll 1976) in slovenska standardna populacija (Popis 2002). Kumulativna incidencna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupi- nah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje. Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost po- sameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), ce ne umre prej zaradi drugih vzrokov. Ocena števila novih primerov za tekoce koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vkljuceni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo. 62Incidenca Umrljivost Prevalenca PreživetjeGroba stopnja Starostno standardizirana stopnja Kumulativna stopnja Kumulativno tveganje Ocena incidence PojmovnikDefinicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA: http://www.slora.si/definicije-kazalnikov-in-metod. Število vseh na novo ugotovljenih primerov raka v tocno doloceni populaciji v enem koledarskem letu. Število vseh umrlih za doloceno boleznijo v tocno doloceni populaciji v enem koledarskem letu. Število vseh bolnikov z doloceno boleznijo, ki so bili živi na izbrani datum (po- navadi zadnji dan v letu). Glede na cas, kdaj so zboleli, locimo: .Celotna prevalenca upošteva vse bolnike z rakom ne glede na to, kdaj so zboleli. .Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v tocno dolocenem obdobju pred datumom izracuna. Na primer, v enoletno delno prevalenco so vkljuceni bolniki, ki so zboleli leto dni pred datumom izracuna ter so na ta datum še živi. Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V porocilu podajamo cisto preživetje, izracunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proucevanega raka (hipoteticen primer, v katerem ne umirajo zaradi drugih vzrokov smrti). Incidenca ali umrljivost, preracunani na velikost opazovane populacije. Obicajno je izražena na 100.000 prebivalcev. Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, ce bi bila starostna struktura te populacije enaka kot je v standar- dni populaciji. Uporabljene so tri standardne populacije: svetovna (Segi 1961), evropska (Doll 1976) in slovenska standardna populacija (Popis 2002). Kumulativna incidencna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupi- nah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje. Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost po- sameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), ce ne umre prej zaradi drugih vzrokov. Ocena števila novih primerov za tekoce koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vkljuceni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo. Glossary63Glossary Definitions of indicators and methods are explained in detail on web portal SLORA: http://www.slora.si/en/definicije-kazalnikov-in-metod. Number of all newly diagnosed cancer cases that develop in a defined popula- tion in one calendar year. Number of all patients who died because of certain disease in a defined popu- lation in one calendar year. Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnosis we distinguish: .Lifetime prevalence is defined as the number of all persons ever diag- nosed with cancer and being alive at a specific time date. .Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation. In groups of patients, survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients’ survival from cancer only(all other causes of death excluded). Incidence or mortality calculated per observed population, usually expressed per 100.000 population. Age-standardization tells what the crude rate would be in observed population, if its age structure were the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slovenian standard population (Census 2002). The cumulative incidence or mortality rate is a special form of direct age stan- dardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk. Cumulative risk is expressed in percentages and interpreted as the risk an indi- vidual would have of developing the disease in question during a certain age range (e.g. up to the age of 74), if there were no other causes of death. Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years. Incidence Mortality Prevalence Survival Crude rate Age-standardized rate Cumulative rate Cumulative risk Estimation of incidence 63Glossary Definitions of indicators and methods are explained in detail on web portal SLORA: http://www.slora.si/en/definicije-kazalnikov-in-metod. Number of all newly diagnosed cancer cases that develop in a defined popula- tion in one calendar year. Number of all patients who died because of certain disease in a defined popu- lation in one calendar year. Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnosis we distinguish: .Lifetime prevalence is defined as the number of all persons ever diag- nosed with cancer and being alive at a specific time date. .Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation. In groups of patients, survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients’ survival from cancer only(all other causes of death excluded). Incidence or mortality calculated per observed population, usually expressed per 100.000 population. Age-standardization tells what the crude rate would be in observed population, if its age structure were the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slovenian standard population (Census 2002). The cumulative incidence or mortality rate is a special form of direct age stan- dardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk. Cumulative risk is expressed in percentages and interpreted as the risk an indi- vidual would have of developing the disease in question during a certain age range (e.g. up to the age of 74), if there were no other causes of death. Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years. Incidence Mortality Prevalence Survival Crude rate Age-standardized rate Cumulative rate Cumulative risk Estimation of incidence POROCILO RR št. 60 REPORT No. 60 Ljubljana 2021 ISSN 1318-5845